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2 Summary 
Atopic eczema is the most common chronic inflammatory skin disease, affecting 10-20% 
of children and 1-3% of adults in industrialized countries. Various genetic, environmental, 
and physiological factors act together in the multifactorial pathogenesis of atopic eczema 
by activating well-known immunological and inflammatory pathways. In addition, IgE-
mediated reactivity against human proteins, so called autoreactivity, has been postulated 
as a further pathogenic mechanism. Already in 1941 it was described that human skin 
dander is able to trigger immediate type skin reactions in patients with severe atopic 
eczema, suggesting that endogenous proteins may serve as targets for IgE 
autoantibodies. However, only the application of modern molecular biology methods led 
to the elucidation of the biochemical nature of these self-antigens. Although several IgE-
binding self-antigens associated with atopic eczema are described in deep detail, the 
whole repertoire of these proteins and their role in the pathogenesis of the disease are 
still largely unknown. Therefore, the aim of this thesis was the identification of new IgE-
binding self-antigens associated with atopic eczema and the characterization of their 
immunological properties and their expression in the skin. 
To identify new IgE-binding self-antigens, a human cDNA library displayed on phage 
surface was screened with solid-phase immobilized serum IgE of patients suffering from 
atopic eczema. 140 complete and partial sequences encoding putative IgE-binding self-
antigens were identified. The presence of nine out of twelve already described self-
antigens among the enriched clones indicated a high specificity of the screening system 
used. Five putative self-antigens namely actin-alpha, tubulin-alpha, eukaryotic initiation 
factor for translation 6, HLA-DR-alpha, and RP1 were randomly selected for cloning, 
expression as His6-tagged fusion proteins in Escherichia coli, and purification by Ni2+-
chelate affinity chromatography. Western blot as well as ELISA experiments confirmed 
that the recombinant self-antigens bind IgE of sera of atopic eczema patients while 
healthy controls had no detectable levels of self-antigen-specific IgE. Moreover, the 
recombinant self-antigens cross-linked receptor bound IgE on the surface of basophils as 
demonstrated by the upregulation of CD63 and CD203c and induced the proliferation of 
peripheral blood mononuclear cells of sensitized patients. Interestingly, 
immunohistochemistry staining of skin biopsies demonstrated that tubulin-α and HLA-DR-
α are upregulated in acute and chronic atopic eczema lesions compared to unaffected 
skin from the same patient or healthy controls. 
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In summary it can be ascertained that the spectrum of IgE-binding self-antigens involved 
in the pathogenesis of AE is much broader than initially expected. Many human proteins 
might serve as IgE-binding self-antigens in atopic eczema and most atopic eczema 
patients have autoreactive IgE-antibodies in serum. Self-antigens are supposed to 
exacerbate the chronic inflammation in the skin by activating the humoral and cellular 
immunity. These results are of considerable significance for the management of atopic 
eczema and the definition of new therapeutic strategies. 
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3 Zusammenfassung 
Mit einer Prävalenz von 10-20% unter Kindern und 1-3% unter Erwachsenen ist das 
atopische Ekzem die häufigste chronisch-inflammatorische Hauterkrankung in den 
Industrieländern. Zahlreiche genetische, physiologische und umweltbedingte Faktoren 
wirken bei der Pathogenese zusammen und aktivieren immunologische und 
inflammatorische Signalwege. Zudem wurden IgE-vermittelte Reaktionen gegen humane 
Proteine als weitere Ursache für die Entstehung des atopischen Ekzems vorgeschlagen. 
Schon 1941 wurde beschrieben, dass menschliche Hautschuppen bei Patienten mit 
schwerem atopischen Ekzem Typ I-Hautreaktionen auslösen können. Diese 
Beobachtungen ließen vermuten, dass auch endogene Proteine IgE-Antikörper binden 
können. Doch erst mit der Anwendung von modernen Methoden der Molekularbiologie 
ließ sich die biochemische Natur dieser Autoantigen aufklären. Obwohl mehrere IgE-
bindende Autoantigene im Zusammenhang mit dem atopischen Ekzem detailliert 
beschrieben sind, ist das gesamte Spektrum dieser Proteine und deren Rolle in der 
Pathogenese des atopischen Ekzems noch weitestgehend unbekannt. 
Das Ziel dieser Dissertation war daher die Bestimmung neuer IgE-bindender 
Autoantigene, die Charakterisierung ihrer immunologischen Eigenschaften sowie die 
Untersuchung ihrer Expression in der Haut. Um neue IgE-bindende Autoantigene zu 
bestimmen, wurde eine humane Phage-Display Bibliothek mit immobilisierten IgE-
Antikörpern aus dem Serum von Patienten mit atopischem Ekzem gescreent. Dabei 
wurden 140 vollständige und partielle DNA-Sequenzen gefunden, die für potentielle IgE-
bindende Autoantigene kodieren. Da unter diesen auch neun von zwölf Autoantigenen 
präsent waren, welche bereits im Zusammenhang mit dem atopischen Ekzem 
beschriebenen sind, scheint das verwendete Screening-System hoch spezifisch zu sein. 
Fünf potentielle Autoantigene, nämlich Aktin-α, Tubulin-α, eukaryotischer 
Translationsinitiationsfaktor 6, HLA-DR-α und RP1 wurden zufällig ausgewählt, kloniert, 
als His6-tagged Fusionsproteine in Escherichia coli exprimiert und mittels 
Affinitätschromatographie gereinigt. Western blot- und ELISA-Experimente bestätigten, 
dass die rekombinanten Proteine IgE im Serum von Patienten mit atopischem Ekzem 
binden, während im Serum von gesunden Kontrollen keine spezifischen IgE-Antikörper 
nachzuweisen waren. Des Weiteren kreuzvernetzen die rekombinanten Autoantigene 
Rezeptor-gebundenes IgE an der Oberfläche von Basophilen, wie die Hochregulierung 
von CD63 und CD203c zeigte, und induzierten die Proliferation von mononukleären 
Zellen des peripheren Blutes von sensibilisierten Patienten. Mittels Immunohistochemie 
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wurde gezeigt, dass Tubulin-α und HLA-DR-α in Biopsien von akuten und chronischen 
Läsionen im Vergleich zu unbetroffener Haut der selben Patienten oder Haut von 
gesunden Kontrollen hochreguliert sind. 
Zusammenfassend kann angenommen werden, dass das Spektrum von IgE-bindenden 
Autoantigenen, die im Zusammenhang mit dem atopischem Ekzem stehen, deutlich 
breiter ist als ursprünglich angenommen. Viele humane Proteine können möglicherweise 
als IgE-bindende Autoantigene dienen und die meisten Patienten mit atopischem Ekzem 
haben autoreaktive IgE-Antikörper. Durch die Aktivierung der humoralen- und zellulären 
Immunität verschlimmern diese Autoantigene scheinbar die chronische Entzündung in 
der Haut. Diese Ergebnisse sind von beachtlicher Bedeutung bei der Behandlung des 
atopischen Ekzems und der Definition von neuen therapeutischen Strategien. 
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4 Abbreviations 
3D three-dimensional 
A. fumigatus Aspergillus fumigatus 
Ab antibody 
ABPA allergic bronchopulmonary aspergillosis 
ADCC antibody-dependent cell-mediated cytotoxicity 
AE atopic eczema 
Ag antigen 
AICD activation-induced cell death 
AIRE autoimmune regulator 
BCR B cell receptor 
CD cluster of differentiation 
cTEC cortical thymic epithelial cell 
CTLA-4 cytotoxic T lymphocyte antigen 4 
DC dendritic cell 
E. coli Escherichia coli 
EAE experimental autoimmune encephalitis 
eIF6 eukaryotic initiation factor for translation 6 
ELISA enzyme-linked immunosorbent assay 
FcR receptor for constant region of an antibody 
FoxP3 forkhead box P3 
GM-CSF granulocyte macrophage growth factor 
GMP good manufacturing practice 
HLA human leukocyte antigen 
IDEC inflammatory dendritic epidermal cell 
IFN interferon 
Ig immunoglobulin 
IL interleukin 
IMAC immobilized metal affinity chromatography 
LAG-3 lymphocyte activation gene-3 
LFA-1 lymphocyte function-associated antigen-1 
LPS lipopolysaccharide 
M. sympodialis Malassezia sympodialis 
MBP myelin basic protein 
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MHC major histocompatibility complex 
MnSOD manganese superoxide dismutase 
mTECs medullary thymic epithelial cells 
PAMP pathogen-associated molecular patterns 
PBMC peripheral blood mononuclear cell 
PCR polymerase chain reaction 
PD-1 programmed death 1 
S. aureus Staphylococcus aureus 
SIT specific immunotherapy 
STAT signal-transducing activators of transcription 
TCR T cell receptor 
TGF transforming growth factor 
Th cell T helper cell 
TLR toll-like receptor 
TNF tumor necrosis factor 
Tr1 type 1 regulatory T cell 
Treg cell regulatory T cell 
TSA tissue specific antigen 
TSLP thymic stromal lymphopoietin 
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5 Introduction 
5.1 Historical background of al lergy 
Today allergic diseases are the most common chronic illnesses in childhood and up to 
30% of adults in Western countries are suffering from allergic rhinitis, allergic asthma, or 
atopic eczema (AE) (1). Allergy, however, is not a new disease but well recognized since 
antiquity: The earliest report of an allergic reaction dates back to 3500 BC when King 
Menses of Egypt was killed by the sting of a wasp. The Greek physician Hippocrates 
(460-357 BC) first described clinical symptoms comparable to asthma and AE. Around 50 
BC the Roman poet and philosopher Titus Lucretius Carus (97-55 BC) observed 
exaggerated responses to commonly occurring substances and wrote in De Rerum 
Natura (On the Nature of Things) “what is food for some may be fierce poisons for others” 
(2). 
The modern era of allergology started in the 1800s with the description of hay fever by 
John Bostock (3), followed by the identification of pollen as causative agents for allergic 
reactions by Charles Blackely in 1873 (4). In 1906 the Austrian pediatrician Clemens von 
Pirquet first introduced the word “allergy” to describe the symptoms, which some 
diphtheria patients developed after treatment with a horse serum antitoxin (5). The word 
derives from the Greek terms “allos” (other) and “ergon” (reaction) and expresses “the 
altered capacity of the body to react to a foreign substance”. Scientific investigations on 
the immunological basis of allergic reactions were initiated by the classic experiment of 
Carl W. Prausnitz and Hans Küstner in 1921: Intradermal injection of serum from a 
sensitized patient to a normal person leads to a local weal and flare response after 
challenging with the sensitizing allergen (6). The identification of immunoglobulin (Ig) E as 
the responsible factor transferring local hypersensitivity (7, 8) marks a major 
breakthrough in understanding the mechanisms of allergy. 
5.2 Hypersensit ivity reactions and IgE-mediated 
al lergy 
In 1968 IgE was described as a novel immunoglobulin subclass (9) and found to be the 
triggering factor for allergic diseases (7). Beside its postulated effects in the protective 
immunity against helminth infections not much is known about the physiological role of 
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IgE antibodies. In contrast, the pathophysiology of IgE-mediated diseases has been 
studied in detail. 
During primary sensitization antigen-presenting cells, mainly dendritic cells (DCs), take 
up and process the antigen and present the resulting peptides via MHC class II 
molecules to naïve T cells (Figure 1). Upon activation naïve T cells differentiate into 
allergen-specific T effector cells. IFN-γ and IL-12 drive the differentiation of naïve CD4+ T 
cells into T helper (Th) 1 cells, whereas exposure to IL-4, IL-5, IL-9, and IL-13 favors the 
differentiation of Th2 cells. They are characterized by the expression of the transcription 
factor GATA-3 and the production of IL-4, IL-5, IL-9, and IL-13 and constitute the 
prominent T cell subset in allergic inflammation (Figure 2). Mature Th2 cells activate 
allergen-specific B cells that differentiate into antibody secreting plasma cells. IL-4 and IL-
13 induce via the transcriptional regulator STAT6 an isotype switch to IgE expression. 
Secreted IgE binds to its high affinity receptor FcεRI on the surface of mast cells, 
basophils, and activated eosinophils. Cross-linking of receptor-bound IgE by specific 
antigens leads to degranulation of the effector cells, resulting in the immediate release of 
various preformed or newly synthesized inflammatory mediators (10). 
Mast cells reside in the connective tissue, most abundantly in the submucosal tissue and 
the dermis. Within seconds upon stimulation they release histamine, a vasoactive amine 
that increases local blood flow and vascular permeability. Enzymes, such as mast cell 
chymase, tryptase, and cathepsin G activate matrix metalloproteinases, which break 
down tissue matrix proteins leading to tissue destruction. TNF-α activates endothelial 
cells that express adhesion molecules to promote the influx of leukocytes and 
lymphocytes into the tissue. Lipid mediators such as prostaglandin D2 or leukotrienes 
cause smooth muscle contraction, increased vascular permeability, and mucus secretion. 
Furthermore, mast cells secrete cytokines such as IL-4 and IL-13 that amplify the allergic 
response by promoting the differentiation of Th2 cells and IgE class switch. IL-3, IL-5, and 
GM-CSF induce eosinophil production in the bone marrow. After release into circulation 
they are attracted to the site of inflammation by eotaxins, produced by leukocytes. By 
releasing toxic granule proteins and free radicals eosinophils are able to kill 
microorganisms but may also cause tissue damage in allergic inflammation (10). 
The recruitment, activation, and effector functions of mast cell, basophils, and eosinophils 
closely correlate. IL-3, IL-5, GM-CSF induce the growth of both basophils and 
eosinophils. Their maturation is, however, reciprocally controlled. Basophils, eosinophils, 
and mast cells are recruited by the same group of CC chemokines, including CCL7, 
CCL13, and CCL5. Prostaglandin D2, which is released by mast cells, recruits 
eosinophils, basophils, and Th2 cells. The degranulation of mast cells and basophils can 
be induced by major basic protein, which is released by eosinophils (10). 
9 
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Figure 1. Type I hypersensitivity reaction. Antigen-presentation by DCs leads to the activation 
and differentiation of Th2 cells that in turn activate naïve B cells. B cells turn into IgE-expressing 
memory B cells and IgE-secreting plasma cells. Secreted IgE binds to FcεRI on basophils and mast 
cells. Specific allergens cross-link receptor-bound IgE, leading to the release of inflammatory 
mediators such as histamine and leukotriens and the symptoms of allergic diseases. 
 
 
Clinically the allergic response is divided into an immediate reaction (type I 
hypersensitivity reaction) and a late phase reaction (Table 1). The immediate response is 
due to the release of preformed or rapidly synthesized molecules such as histamine or 
prostaglandins, respectively. After 7-9 hours the late-phase-reaction develops in about 
50% of patients with an immediate reaction. Newly synthesized lipid mediators, cytokines, 
and chemokines recruit additional leukocytes and Th2 cells to the site of inflammation, 
resulting in edema and tissue remodeling by increased numbers and enhanced growth of 
smooth muscle cells. 
In contrast to type I hypersensitivity reactions, type II and III hypersensitivity reactions are 
mediated by IgG antibodies. Binding of cell surface and matrix-associated allergens (type 
II) or soluble antigens (type III) activates complement-meditated and phagocytic effector 
mechanisms, leading to drug allergies or serum sickness and systemic lupus 
erythematosus, respectively. 
Type IV hypersensitivity reactions are characteristic for long lasting allergic inflammations 
that reach a chronic stage and lead to severe long-term illness, such as chronic allergic 
asthma or AE. These type IV hypersensitivity reactions are mediated by both Th1 and 
Th2 cells and their specific cytokines IFN-γ and IL-4, IL-5, and IL-13, respectively (10). 
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 Type I Type II Type III Type IV 
Immune 
mechanisms 
IgE-mediated IgG-mediated immune complex-
mediated, IgG-
mediated 
T cell-mediated 
Antigen soluble cell- or matrix-
associated 
soluble soluble or cell-
associated 
Effector 
mechanism 
cross-linking of 
FcεR-bound IgE on 
mast cells and 
basophils leads to 
their degranulation 
cell- or matrix-bound 
Ag induce 
opsonization and 
phagocytosis of 
cells, the activation 
of the complement 
cascade, and 
antibody-dependent 
cell-mediated 
cytotoxicity (ADCC) 
Ag-Ab complexes 
deposited in various 
tissues induce 
activation of the 
complement 
cascade and 
infiltration of FcR+ 
cells 
sensitized Th1 cells 
release cytokines 
that activate 
macrophages, 
eosinophils, or 
CTLs, leading to 
tissue injury or 
direct cell killing 
Symptoms allergic rhinitis, 
acute allergic 
asthma, acute 
atopic eczema, 
systemic 
anaphylaxis 
drug allergies, blood 
transfusion 
serum sickness, 
Arthus reaction, 
systemic lupus 
erythematosus 
contact dermatitis, 
chronic allergic 
asthma, chronic 
atopic eczema, graft 
rejection 
Time to 
develop 
minutes hours hours to weeks two to three days 
 
Table 1. Hypersensitivity reactions. In 1963 Coombs and Gell classified hypersensitivity 
reactions into four types according to the immunological mechanisms, cells, and mediator 
molecules causing tissue damage (11). (Adapted from Abbas AK et al. (12) and Murphy KM et al. 
(10)) 
5.3 Immunological tolerance 
The mammalian immune system possesses the remarkable capacity to defend against 
numerous invading pathogens while maintaining immunological unresponsiveness to self-
antigens. By suppressing immune responses deleterious to the host, immunological 
tolerance is crucial for a healthy immune response and the prevention of autoimmunity or 
allergic diseases. Ensuring self-tolerance within the lymphocyte repertoire is exerted at 
two levels: Central tolerance refers to the deletion of developing autoreactive B and T 
cells that bind self-antigens in the bone marrow or thymus, respectively. Despite stringent 
selection, not all lymphocytes capable of recognizing self-antigens are eliminated during 
their development. Those cells that evade central tolerance are controlled by peripheral 
regulatory mechanisms including ignorance, anergy, phenotypic skewing, tolerogenic 
DCs, and regulatory T (Treg) cells. 
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5 .3 .1  Cent ra l  to le rance  
In humans a T cell repertoire of approximately 25 million specificities has been described 
(13). However, during the maturation of thymocyte progenitors in the thymus random 
gene rearrangements also lead to useless or even harmful receptor specificities. Positive 
selection is the first step in central tolerance and leads to the enrichment of MHC-
restricted T cell progenitors. Thereby double-positive T cell progenitors interact with 
cortical thymic epithelial cells (cTECs) in the thymus cortex. Binding of the lymphocytes’ T 
cell receptor (TCR) to self-peptide-MHC complexes on cTEC allows the further 
differentiation of T cell progenitors while progenitors with no or low affinity die by neglect 
(14). Surviving double-positive progenitors express the chemokine receptor CCR7 and 
migrate towards the thymic medulla where negative selection takes place (15, 16). 
Negative selection is crucial to eliminate potential autoreactive cells generated during 
positive selection. Therefore medullary thymic epithelial cells (mTECs) that express 
costimulatory molecules and peripheral tissue specific antigens (TSAs) under the control 
of the transcriptional regulator AIRE, interact with T cell progenitors during the transition 
from double-positive to single-positive stage (14). Beside mTECs also DCs present in the 
medulla are able to induce negative selection by cross-presenting TSAs generated by 
mTECS and the expression of costimulatory molecules such as CD40, CD80 and CD86 
(17). High affinity binding of TCR to self-antigens presented by mTECs or DCs induces 
clonal deletion or anergy of both CD4+ and CD8+ T cells. Very high affinity for self-
peptides is supposed to induce the differentiation of natural Treg cells that regulate 
immune responses in the periphery and maintain self-tolerance (18, 19). 
 
Similar mechanisms occur in the bone marrow during development of immature B cells: 
Binding of IgM to multivalent self-antigens, for example to ubiquitous surface molecules 
such as MHC, induces clonal deletion of immature B cells. These cells either undergo 
apoptosis or receptor editing by secondary gene rearrangements of the light chain loci. 
The interaction of progenitor B cells with soluble self-antigens, which are able to cross-
link the B cell receptor (BCR) renders these cells anergic to the antigen. They migrate to 
the periphery, but do not respond to the antigen and are rapidly lost in competition with 
other B cells. Immature B cells that bind monovalent antigens or self-antigens with very 
low affinity, which are not able to cross-link the BCR do not receive a negative signal and 
develop normally. However, those cells are clonally ignorant since their specific ligand is 
present but not able to activate them (20). 
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5 .3 .2  Per iphera l  to lerance  
Although central tolerance is a crucial mechanism to avoid the development of 
autoreactivity, not all self-reactive lymphocytes are deleted in the thymus or bone 
marrow. Some TSAs are represented on the mRNA level, but not necessarily on the 
protein level in the thymus. Moreover, extremely stringent negative selection would 
narrow the repertoire of available TCR specificities that respond to foreign pathogens 
(21). Therefore, some T cells with a degree of self-reactivity escape deletion and exit the 
thymus. Indeed, healthy individuals have autoreactive T cells with low-affinity TCR for 
self-antigens in the periphery (22, 23). These autoreactive cells are controlled by T cell 
intrinsic mechanisms acting directly on the self-reactive T cells and by T cell extrinsic 
mechanisms including tolerogenic DCs and Treg cells. 
 
Four T cell intrinsic mechanisms to control self-reactive T cells have been described: 
ignorance, anergy, phenotype skewing, and apoptosis. Ignorance occurs if the antigen is 
anatomically separated and not accessible for effector T cells (24) or does not reach the 
threshold required to trigger a T cell response (25). Anergy refers to a state of 
unresponsiveness to a specific antigen and was first reported as the results of TCR-
ligation in the absence of co-stimulation in vitro (26). Later studies demonstrated that 
activation of inhibitory receptors such as CTLA-4 and PD-1 by CD80/86 and PDL1/2, 
respectively, plays a role in the induction of anergy (27-29). Phenotype skewing 
describes the observation that self-reactive T cells undergo full activation, but develop a 
non-pathogenic phenotype in terms of cytokine and chemokine receptor expression. For 
example Th2 cytokines are shown to downregulate autoimmunity and altered lymphocyte 
trafficking may prevent the migration of autoreactive T cells to B cell areas in lymphoid 
organs (30, 31). Finally, self-reactive T and B cells can die by activation-induced cell 
death (AICD) (32). Thereby contact with self-antigens leads to the upregulation of Fas-
ligand and apoptosis by signaling through the death receptor Fas (CD95). AICD is not 
supposed to eliminate autoreactive T cell precursors completely, but is supposed to 
reduce their numbers to a level where anergy can be efficiently induced. 
 
The T cell extrinsic mechanisms controlling autoreactivity include tolerogenic DCs and 
Treg cells. Whether any immature DC is able to induce tolerogenic functions or whether 
this task is mediated by a specific DC subset is not known. Following exposure to 
pathogen-associated molecular patterns (PAMPs) or intracellular products released 
during cellular damage, immature DCs modify their antigen-processing capacity and their 
surface phenotype. The high expression of costimulatory molecules such as CD80/86 
and CD40 allows the activation of T cells and the initiation of an immune response (10). 
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Consequently, the absence of PAMPs and the low expression of costimulatory molecules 
by DCs leads to anergy or clonal deletion rather than T cell activation (33, 34). Moreover, 
it is assumed that immature or tolerogenic DCs maintain tolerance by inducing Treg cells 
(35), a distinct subset of T cells with regulatory functions (see chapter 5.3.3). 
5 .3 .3  Regula tory  T  ce l ls  
Treg cells are able to inhibit autoreactivity as well as allergic responses and are important 
in maintaining allergen-specific peripheral tolerance (36). Different subsets of Treg cells 
have been described, including induced Tr1 cells (37), Th3 cells (38), and naturally 
occurring CD4+ CD25+ FoxP3+ Treg cells (39, 40). The latter develop in the thymus, 
express the transcription factor forkhead box P3 (FoxP3), and display a T cell receptor 
repertoire that is specific for self-antigens. In contrast to naturally occurring Treg cells, the 
generation of Tr1 and Th3 cells can be induced by IL-10 and transforming growth factor-β 
(TGF-β) in peripheral tissues (Figure 2) (41). Moreover, high dose of allergen exposure 
induces a rapid switch and expansion of IL-10-producing Tr1 cells in non-allergic 
individuals (42). 
The development and function of Treg cells are regulated by an IL-2-mediated negative 
feedback loop. FoxP3 together with other transcription factors and cofactors represses 
the transcription of IL-2 in Treg cells and renders them highly dependent on exogenous 
IL-2. Antigenic stimulation of T effector cells induces the secretion of IL-2, which binds to 
its high-affinity receptor on Treg cells and in turn contributes to the maintenance, 
expansion, and activation of natural Treg cells and facilitates the TGF-β dependent 
differentiation of induced Treg cells (43). 
Beside CD4+ and CD8+ T cells, Treg cells also suppress the activities of natural killer 
cells, natural killer T cells, B cells, macrophages, osteoclasts, and dendritic cells by 
various synergistic suppressive mechanisms (43, 44). Upon antigenic stimulation in the 
thymus Treg cells are recruited via chemokines to DCs. The high expression of adhesion 
molecules such as LFA-1 by Treg cells allows long-lasting contact between Treg cells 
and DCs, leading to out-competition of naïve T cells and prevention of their activation. In 
addition, Treg cells are able to modulate the maturation and function of DCs, which are 
required for the activation of effector T cells. LAG-3 on the surface of Treg cells binds to 
MHC class II molecules on immature DC and blocks their maturation. Upon interaction 
between CTLA4 and CD80 or CD86 DC secrete indoleamine 2,3-dioxygenase (IDO), an 
immunosuppressive mediator, which induces the production of pro-apoptotic molecules in 
effector T cells (45). Treg cells also kill or inactivate effector T cells directly by secreting 
inhibitory cytokines such as IL-10, TGF-β, and IL-35 that suppress the generation and 
activation of effector cells (46, 47). The release of granzyme A and B together with 
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perforin mediates cytolysis of target cells (48). In addition Treg cells are supposed to elicit 
metabolic disruption in effector cells. High-level expression of CD25 (IL-2 receptor α) by 
Treg cells leads to the local consumption of IL-2, resulting in cytokine-deprivation and 
apoptosis of dividing effector T cells (49). Finally, released adenosine and cAMP are able 
to inhibit effector T cell function through binding of the adenosine receptor 2A on the cell 
surface or by direct transfer into effector cells via gap junctions, respectively (50, 51). 
The concentration of antigenic peptides required to activate Treg cells is estimated to be 
10- to 100-fold lower than the concentration needed to activate naïve T cells (52). Thus, 
Treg cells may prevent autoimmunity induced by molecular mimicry because Treg cells 
are more easily activated by suboptimal T cell receptor ligand concentrations than cross-
reactive T cells (53). 
 
 
 
 
Figure 2. Differentiation of naïve CD4+ T cells into Treg cells or effector T cells. CD4+ T cells 
differentiate into FoxP3+ natural Treg cells (nTreg) in the thymus or migrate into the periphery 
where they differentiate into induced Treg cells (iTreg), Th1, Th2, or Th17 cells, depending on the 
cytokines present. The transcription factors T-bet, GATA-3, RORc-2, and FoxP3 are required for 
the differentiation of naïve T cells into Th1, Th2, Th17, and Treg cells, respectively. (Adapted from 
Sakaguchi S et al. (43)) 
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In healthy individuals Treg cells constitute the major T cell subset specific for 
environmental allergens, whereas in allergic patients IL-4 secreting Th2 cells 
predominate (54). Treg cells are supposed to prevent allergic symptoms by suppressing 
the generation and effector functions of T cells, eosinophils, mast cells and basophils. IL-
10 and TGF-β inhibit the production of IgE but induce the secretion of non-inflammatory 
antibodies of the IgG4 and IgA isotype in B cells (55). Suppressed Th2 cells can neither 
provide cytokines such as IL-4 and IL-13, which induce class-switch to IgE, nor support 
the differentiation, the survival, and the activation of eosinophils, mast cells, and 
basophils by IL-3, IL-4, and IL-5. In addition, suppressed Th1 cells do not mediate tissue 
injury such as apoptosis of skin keratinocytes or bronchial epithelial cells. 
5.4 Atopic diseases 
The immune system is crucial for human health and survival by providing host defense 
against infectious agents. However, sometimes immune responses mount against 
antigens, which are not associated with pathogens, and lead to severe diseases: Immune 
responses against self-antigens result in autoimmunity characterized by chronic 
inflammation and tissue damage, whereas undesirable reactions against harmless 
environmental antigens such as pollens, animal dander, moulds, or food are the cause of 
allergic diseases. 
Allergen-specific IgE antibodies are necessary, but not sufficient to develop allergic 
diseases. However, about 40% of individuals sensitized to inhalant allergens are 
asymptomatic (56). This finding demonstrates that beside environmental factors also 
genetic predisposition contributes to the development of allergic diseases. In so-called 
atopic individuals with elevated serum IgE levels and increased numbers of eosinophils, 
several susceptibility genes on different loci increase the risk of developing AE, allergic 
rhinitis, or allergic asthma. 
Usually the onset of AE occurs during the first 6 months of life and frequently improves 
during childhood. However, around 40% of children suffering from AE undergo the atopic 
march and develop allergic rhinitis or allergic asthma, respectively (57). 
5 .4 .1  Atop ic  eczema 
AE is the most common inflammatory skin disorder affecting 10-20% of children and 1-
3% of adults in industrialized countries (58, 59). It presents as a relapsing, highly pruritic 
inflammation during infancy but can also persist or start in adulthood. The pathogenesis 
of AE is multifactorial, based on a strong genetic predisposition and triggered by various 
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environmental and physiological factors, leading to skin barrier dysfunction and chronic 
inflammation (Figure 3). 
80% of the AE patients suffer from the atopic form of the disease (previously called 
extrinsic AE), which is characterized by elevated levels of total serum IgE (>150 kU/l), 
accompanied with sensitizations to environmental allergens, allergic rhinitis, or allergic 
asthma. In contrast, patients with non-atopic eczema (intrinsic AE) show normal levels of 
total serum IgE but eczematous skin lesions, which are clinically and histologically 
indistinguishable from those observed in extrinsic atopic eczema (60, 61). 
 
 
 
 
Figure 3. Clinical finding of AE. In infancy first eczematous lesions usually emerge on the 
cheeks, the forehead and the scalp. Scratching causes crusted erosions. 
 
 
Immunologically the pathogenesis of extrinsic AE has a biphasic nature: It is initiated by a 
type I hypersensitivity reaction characteristic during the acute phase, followed by a 
characteristic type IV hypersensitivity reaction during the chronic phase of the disease 
(Figure 4). During the acute phase antigen-presenting Langerhans cells in the epidermis 
favor the differentiation of naïve T cells into Th2 cells secreting IL-4, IL-5, and IL-13, 
which induces an isotype switch to IgE expression in B cells. Chemokines that are 
expressed by endothelial cells and keratinocytes attract leukocytes to the site of 
inflammation. For instance, in acute AE increased serum levels of monocytes 
chemoattractant protein-1 (MCP-1), macrophage inflammatory protein (MIP-1β), eotaxin, 
IL-16, and RANTES are observed (62). High numbers of recruited mast cells secrete 
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histamine, which induces pruritus by binding to histamine H3 receptors on sensory 
nerves. Moreover, histamine acts as a leukocyte chemoattractant and upregulates the 
production of various inflammatory chemokines and cytokines such as IL-6, IL-8, and 
GM-CSF by keratinocytes via histamine H1 receptors (63). The migration of memory and 
effector T cells to the inflammed skin is mediated predominantly by cutaneous 
lymphocyte antigen (CLA) and the chemokines CCL27 and CCL18. Langerhans cells 
residing in the epidermis express FcεRI on their surface and aggregation of the receptor 
leads to the release of additional chemotactic factors such as IL-16, CCL22, and CCL17 
and the recruitment of inflammatory dendritic epidermal cells (IDEC) (64). Moreover, the 
IL-7-like cytokine thymic stromal lymphopoietin (TSLP) released by epithelial cells further 
enhances the secretion of IL-16 from Langerhans cells and the recruitment of CD4+ T 
cells, monocytes, and IDEC. In contrast to Langerhans cells, IDEC are found exclusively 
at inflammatory sites. Upon FcεRI cross-linking they secrete IL-12 and IL-18 and enhance 
the priming of naïve T cells into Th1 cells, which dominate the inflammatory response 
during the chronic phase of AE (Figure 2, Figure 4). In contrast to psoriatic lesions, low 
numbers of Th17 cells are found in AE lesions (65) and naturally occurring CD4+ CD25+ 
FoxP3+ Treg cells are found to be absent from AE lesions (66). 
By expressing membrane-bound and soluble Fas ligands (FasL) as well as IFN-γ Th1 cell 
induce keratinocyte apoptosis (67), leading to disruption of the skin barrier. Moreover, a 
slight, prolonged alkalinization from pH 5.0 to pH 5.5 in the skin of AE patients sustains 
the activity of serine proteases, which are involved in the proteolysis of 
corneodesmosomes and lipid processing enzymes (68). Degradation of 
sphingomyelinase results in decreased content of ceramides and an altered lipid layer 
(69). In addition impaired expression of cornified envelope proteins such as filaggrin and 
keratins promotes the skin barrier dysfunction, leading to transepidermal water loss and 
invasion of bacteria, viruses, and allergens (69). 
Two hypotheses concerning the initial event in the pathogenesis of AE have been 
proposed (70): One states that epithelial-barrier dysfunction is the consequence of the 
local inflammation. The other considers intrinsic defects in the epithelial cells as the 
cause of barrier dysfunction, and the local inflammation induced by invading allergens, 
bacteria, and viruses as epiphenomenon. 
Decreased expression of antimicrobial peptides such as defensins and cathelicidins (LL-
37) favors the colonization of lesional and unaffected skin by different microorganisms, 
including bacterial and fungal species (71, 72). Particularly, infections with 
Staphylococcus aureus (S. aureus) were found to trigger AE: S. aureus stimulates the 
production of GM-CSF and CCL5 in keratinocytes (73), and releases enterotoxins, which 
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act as superantigens, induce the pruritic cytokine IL-31 in T cells (74, 75), and neutralize 
the suppressive function of Treg cells (76). 
Beside microbial infections, also exposure to allergens triggers the cutaneous 
inflammation. While children are mainly sensitized against food allergens such as milk, 
egg, wheat, or soy, adults frequently show specific IgE antibodies against house dust 
mites or the skin colonizing yeast Malassezia (77, 78). Malassezia sympodialis (M. 
sympodialis) is found on the skin of healthy individuals as well as on unaffected skin and 
inflammed lesional skin of AE-patients. However, 30-80% of AE-patients are sensitized 
against M. sympodialis and IgE specific for Malassezia was found to be restricted to 
atopic and non-atopic eczema. Sensitization to this particular yeast does not occur in any 
other allergic diseases (78). To date 3 allergens from M. furfur and 10 from M. 
sympodialis are known. While some allergens like Mala s 1 are species-specific (79), 
others are phylogenetically highly conserved. Mala s 6 (80), Mala s 11 (81), and Mala s 
13 (82) show sequence similarity and cross-reactivity with the corresponding human 
proteins (see chapters 5.6.3). Autoreactivity to human self-antigens due to molecular 
mimicry with environmental allergens might be of pivotal importance for the exacerbation 
of chronic AE (see chapter 5.6.4) (83). 
 
 
Figure 4. Acute and chronic phase of AE. In the acute phase of AE, binding of allergens 
activates Langerhans cells that present allergen-derived peptides to T cells and induce a Th2 
profile. The secretion of IL-16 and MCP-1 attracts monocytes. After migration into the skin the 
recruited monocytes differentiate into IDECs. By the secretion of IL-12 and IL-18 IDECs favor the 
differentiation of Th1 cells, which constitute the major T cell subset during chronic atopic eczema. 
(Adapted from Bieber T et al. (70)) 
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AE has a high familiar occurrence; studies of twins with AE have demonstrated 
concordance rates of 0.72 in monozygotic and 0.23 in dizygotic twin pairs (84). However, 
various genetic and epidemiological studies demonstrated that not a single gene can be 
implicated as the gene responsible for the development of AE, but various candidate 
genes and polymorphisms of immune regulatory genes, atopy related genes, and skin-
specific genes play a role in the pathogenesis of AE. For instance mutations in the genes 
for filaggrin (85, 86) and stratum corneum chymotryptic enzyme (87) lead to impaired 
dermal differentiation, integrity and function of stratum corneum. Genetically based 
modifications of toll-like receptor (TLR) 2 (88), eotaxin (89), C3 (90), and RANTES (91) 
(92) or of cytokines like IL-4 (93), IL-18 (94), TGF-β (95), and GM-CSF (96) result in 
altered innate and adaptive immunity, respectively. Mapping of susceptibility loci 
identified by genome screens for AE, allergic asthma, and psoriasis demonstrated an 
overlap between susceptibility genes for AE and psoriasis but little overlap between AE 
and allergic asthma (97), indicating that specific genetic factors are involved in both 
diseases. 
5 .4 .2  A l le rg ic  rh in i t is  
Allergic rhinitis is a frequent inflammatory disease of the upper airways resulting from the 
activation of mucosal mast cells beneath the nasal epithelium. Usually allergic rhinitis 
already begins in childhood, and often persists through adolescence and early adulthood, 
but tends to wane in older adults. The prevalence of allergic rhinitis was found to be in the 
range of 25% in European children aged 5-13 years (98). Thus, allergic rhinitis represents 
the most frequent allergic disease. 
Two forms of allergic rhinitis are distinguished by time of allergen exposure: Seasonal 
allergic rhinitis is mainly triggered by pollen from trees, grass, and weed, while house 
dust mites, animal dander, cockroaches, and moulds are the cause of perennial allergic 
rhinitis. The immediate phase response occurs within minutes after allergen-exposure 
and induces repetitive sneezing, itching of the eyes, nose, and throat, and watery 
rhinorrhea. After 4-8 hours the late phase response begins, which is characterized by 
congestion, fatigue, and malaise. Although allergic rhinitis is not life-threatening, it has a 
important impact on the quality of life, mainly by sleep disturbance, which in turn leads to 
impaired concentration and work performance (99). Several epidemiological and clinical 
studies report a close relationship between allergic rhinitis and allergic asthma. 
Frequently allergic rhinitis during childhood is followed by adult-onset allergic asthma 
(100). 
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5 .4 .3  A l le rg ic  as thma 
Compared to AE or allergic rhinitis, allergic asthma is a more serious syndrome leading to 
frequent emergency department visits and 13 deaths per million in the United States in 
2004 (101). 
The acute phase of allergic asthma is a type I hypersensitivity reaction, initiated by an 
allergic response to a specific allergen, such as pollen, house dust mites, animal dander, 
or mould spores. The activation of antigen-specific Th2 cells and submucosal mast cells 
in the lower airways leads within minutes to severe narrowing of airway lumen by 
bronchial constriction and increased secretion of fluid and mucus, manifesting by 
wheezing, coughing, dyspnea, and chest tightness. The acute phase is followed by a 
chronic phase of allergic asthma, which is characterized by a type IV hypersensitivity 
reaction, the infiltration of Th2 and Th1 cells into the lung, and airway remodelling due to 
hyperplasia and hypertrophy of smooth muscle cells, apoptosis of airway epithelial cells, 
goblet-cell metaplasia, and fibrosis. 
While the acute phase of allergic asthma is initially driven by allergen-exposure, the 
chronic inflammation is also perpetuated by exposure to cigarette smoke, diesel exhaust 
particles, exercise, and viral or bacterial infections in the absence of specific allergens 
(102). 
5 .4 .4  A l le rg ic  bronchopulmonary asperg i l los is  
Allergic bronchopulmonary aspergillosis (ABPA) was first described in the 1950s as a 
hypersensitivity reaction to the moulds Aspergillus fumigatus (A. fumigatus), Aspergillus 
niger, and Aspergillus flavus that colonize the bronchi (103). In contrast to invasive 
aspergillosis, which is mainly observed in immunocompromised individuals, ABPA occurs 
in immunocompetent individuals; 7-14% of corticosteroid-dependent asthmatics or cystic 
fibrosis patients develop ABPA (104, 105). Aspergillus spores are ubiquitous in soil and 
are commonly found in the sputum of healthy individuals. Upon inhalation of the spores, 
they germinate in the patients’ airways and elicit Th2-medited asthmatic reactions. The 
release of mycotoxins and proteolytic enzymes by the fungus leads to mucus secretion 
and bronchiectasis, characterized by irreversible destruction and widening of the airways 
(106). 
Interestingly, certain A. fumigatus allergens such as Asp f 4 and Asp f 6 are specific 
markers for ABPA and thus, recombinant Asp f 4 and Asp f 6 allow the diagnostic 
discrimination between ABPA and simple A. fumigatus allergy (107). 
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5 .4 .5  A l le rg ic  contact  dermat i t is  
Allergic contact dermatitis is a cell mediated type IV hypersensitivity reaction, affecting 
around 20% of the population with nearly the same prevalence among children and 
adolescents (108). Upon exposure to a contact allergen, antigen-specific Th1 cells 
activate macrophages to secrete chemokines, cytokines like IL-1 or TNF-α, and 
cytotoxins like nitric oxide that lead to tissue damage and allergic symptoms such as local 
redness, edema, warmth, and pruritus. Many contact allergens are known, including 
latex, poison ivy, poison oak, nickel, and various substances present in cosmetic 
products and hair dyes as the most common ones (109). Although contact eczema may 
persist life-long, the eczema usually heals rapidly when exposure to antigen is avoided. 
5.5 Epidemiology of atopic diseases 
5 .5 .1  Preva lence  and  c l in ica l  s ign i f icance  
During the last century the prevalence of allergic diseases has tremendously increased 
worldwide and thus allergy is frequently referred to as epidemic of the 21st century. For 
instance, between 1979 and 1990 the hospitalizations of asthmatic children has 
increased 20-fold in the United States (102). While 1964 around 19% of Australian 
children were found to suffer from asthma or wheezing at some time during their first 7 
years of life, in 1990 such symptoms were reported for 46% of children (110). 
In general, allergic asthma, AE, and allergic rhinitis are more common in Western 
societies compared to developing countries. Phase II of the International Study of Asthma 
and Allergies in Childhood (ISAAC) reports a prevalence of asthma between 2% and 3% 
among 6 to 7 year-old children in Indonesia or Ethiopia, whereas 28% of Australian and 
23% of British children ever had asthma (111). In 2007 ISAAC Phase III showed that the 
asthma prevalence still rises in regions where the prevalence was low but decreases or 
remains stable in most regions where the prevalence was previously high (112). Several 
factors are discussed to account for the increasing prevalence of allergy, such as 
exposure to tobacco smoke, diesel exhaust particles, or air pollution, increased exposure 
to allergens, and changes in lifestyle accompanied with decreased levels of exposure to 
microbial substances or infections. The relationship between hygiene, exposure to 
microbial sources, and allergy led to postulate the hygiene hypothesis (see chapter 
5.5.2). 
Although allergic diseases, except insect venom allergy, are rarely life-threatening they 
markedly reduce the quality of patients’ life and cause much distress and financial costs. 
Considering the direct costs for life-long medication as well as the indirect costs by lost 
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time from work and reduction of productivity, allergic diseases account for more than € 35 
billion health care burdens only in Europe per year (113). 
5 .5 .2  The  hyg iene  hypothes is  
Allergic disorders clearly have a heritable component; however, the rapidity of the 
epidemiological changes indicates that primarily environmental factors are responsible for 
the recent rise in allergy prevalence. The hygiene hypothesis states that a reduction of 
infectious stressors during early childhood leads to increased longevity on the one hand, 
and to increased prevalence of allergy on the other hand (114). Infectious and non-
invasive microbial exposure is supposed to guide the development of the immune system 
during the first years of life. Microbial compounds activate the innate immune system via 
TLRs. TLR-signaling pathways are believed to lead to the expansion of Th1 cells and at 
the same time to the suppression of the generation of Th2 cells, IgE, and Th2-dependent 
diseases (115). Supporting this hypothesis various epidemiological studies found an 
inverse correlation between atopy and the number of older siblings, early day-care 
attendance, the use of antibiotics, residence on a farm, and the consumption of 
unpasteurized cow’s milk early in life (116, 117). 
In addition helminth infections are found to prevent the development of allergy (118) and 
anti-helminth therapy is reported to lead to a significant increase in allergic skin 
sensitization among children from Venezuela and Gabun (119, 120). Helminths are 
supposed to activate a systemic anti-inflammatory network by the upregulation of IL-10 
and TGF-β and the induction of Tregs (118). Moreover, parasitic nematodes secrete ES-
62, a TLR-4 agonist, which inhibits the FcεR-induced release of allergy mediators from 
mast cells (121). 
Although the hygiene hypothesis is considered as a valid model to explain many of the 
observed differences in asthma prevalence among populations, some recent studies 
point out its limitations: Changes in the asthma prevalence were described while the way 
of life and the housing conditions were kept constant (122, 123). Not all early childhood 
infections inhibit the tendency to develop allergic diseases and some respiratory virus 
infections are even positively associated with the development of asthma (124, 125). 
Moreover, not all helminth parasites are found to have protective effects on the outcome 
of allergic diseases and studies on the interactions between helminths, allergy, and 
immune responses show variable results depending on the species of helminths, the age 
when the infection was acquired, and the intensity of infection (118). 
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5.6 Allergens 
Allergens are substances able to induce a primary sensitization, to bind IgE antibodies, 
and to elicit an allergic reaction. Most allergens are proteins, but also haptens such as the 
penicilloyl group, or certain glycosidic side chains from plant proteins, insect venom, or 
seafood were found to bind IgE. 
Today more than 700 allergens have been identified and their sequences determined, 
including pollen, plant, and food allergens as well as indoor allergens from house dust 
mites, animal dander, and moulds. The list of described allergens is still continuously 
growing and updated information can be retrieved from databases such as the Official 
List of Allergens issued by the International Union of Immunological Societies Allergen 
Nomenclature Sub-committee (http://www.allergen.org), the Allergome database 
(http://www.allergome.org), the Food Allergy Research and Resource Program Allergen 
Database (http://www.allergenonline.com), or the InformAll database 
(http://foodallergens.ifr.ac.uk/). All allergens are named according to a standardized 
nomenclature, starting with 3 letters indicating the genus, followed by a single letter for 
the species, and a number for chronological order of allergen identification. 
5 .6 .1  What  makes  an  ant igen  an  a l le rgen? 
To date it is not exactly known, why certain foreign proteins elicit allergic reactions, 
whereas other ones, which encounter the immune system via the same route of 
exposure, are tolerated. The allergenicity of a certain protein depends on its solubility, 
size, compactness of the overall fold, stability in the tissue, and the concentration in the 
corresponding allergen extract. Thus, they are subdivided into minor and major allergens. 
By definition a major allergen binds IgE in sera from more than 50% of the patients 
sensitized to the corresponding extract (126). Moreover, additional substances present at 
the time of allergen exposure either from the allergen extract itself such as lipids in pollen 
or from another source such as air pollution in the form of e.g. diesel dust or 
nanoparticles, or bacterial and viral infections can enhance the primary sensitization and 
secondary immune response to allergens. 
All allergens described are heterogeneous in regard to their size and function. Structural 
and functional studies have failed to identify unifying properties or structural motifs 
characteristic for all allergens. Thus, for a long time it was considered that any antigen, 
which comes into contact with the immune system in sufficient amounts and in the 
appropriate context, might elicit an allergic response. 
However, most allergens can be grouped into a small number of protein families and 
possess a limited range of biochemical functions such as hydrolysis of proteins, binding 
of metal ions and lipids, transport, storage, or they are associated with the cytoskeleton 
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(127, 128). The connection between biochemical function and allergenicity is best 
understood for Der p 1, the major allergen from the house dust mite. Der p 1 is a cystein 
protease that cleaves the tight junction protein occludin, leading to increased epidermal 
permeability and facilitated entry of Der p 1 into the tissue (129). 
Today the prediction of allergenicity of a certain protein by bioinformatics is only possible 
to a very limited extend (130) but is of great interest when new proteins are introduced 
into our environment, for instance in genetically modified foods or as biological in 
medicine. Therefore the in silico prediction of allergenicity constitutes a challenging topic 
for future research. 
5 .6 .2  Recombinant  a l le rgens  
In 1988 Der p 1, the first recombinant allergen, was cloned (131) and since then 
numerous others followed. Today information about the allergen sequence together with 
cDNA from the allergen source allows the rapid cloning by PCR, recombinant production, 
and purification of allergenic molecules, which are crucial for elucidating the 
immunological mechanisms of allergy, but also for diagnostic and therapeutic use. 
Since cloning of recombinant allergens necessarily depends on the availability of 
information on the allergen sequence, the identification of allergens from a given allergen 
source is of outmost importance. Screening of cDNA libraries with serum IgE from allergic 
patients allows the selective enrichment of clones expressing IgE-binding molecules and 
the determination of their primary structure. Frequently cDNA libraries displayed on 
phage surface are used to isolate new allergens such as allergens from Aspergillus (132), 
Malassezia (133), Cladosporium (134), peanut (135), wheat (136), and maize (136). 
Phage surface display technology exploits the linkage between phenotype, expressed as 
gene product displayed on the phage coat, and genotype, defined by the genetic 
information integrated into the phage genome. Moreover, phage display technology is 
adaptable to robotic based high-throughput screening technology, ensuring rapid and 
cost-efficient identification of a large number of IgE-binding antigens and fast 
determination on their sequences (137, 138). 
The recombinant expression of allergens is possible in different host cells; the most 
appropriate one, however, has to be established for each protein considering its 
subsequent application. Escherichia coli (E. coli) is a suitable host for high-level 
expression of recombinant proteins, but lacks the capacity of post-transcriptional 
modifications, which sometimes are necessary for IgE-binding (139). Moreover, bacterial 
contaminants in purified protein solutions may interfere with cellular assays in vitro or 
lead to toxicity in vivo (140). Eukaryotic expression systems such as yeast cells (141), 
insect cells after baculovirus infection (142), or plant cells after tobacco mosaic virus 
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infection (143) might overcome these limitations and have been used for the production 
of glycosylated, pure recombinant allergens (144). 
Several powerful techniques for purification of recombinant proteins are available, but the 
most frequently one used at laboratory scale is affinity chromatography, particularly 
immobilized metal affinity chromatography (IMAC), which allows efficient purification of 
recombinant His6-tagged fusion proteins in a single step. Ion-exchange and size 
exclusion chromatography are suitable methods for further removal of contaminants 
deriving from host cells. 
Both diagnosis and immunotherapy of allergic diseases are primarily based on aqueous 
allergen extracts. They consist of complex mixtures of proteins, while only a few of them 
are allergenic. Allergen extracts are difficult to standardize and large differences in 
allergen content between different batches of extracts and between extracts from 
different manufacturers were found (145). In contrast, recombinant proteins equal their 
natural counterparts in allergen extracts but are producible in consistent pharmaceutical 
quality under GMP conditions, avoiding problems associated with extract standardization 
(146, 147). 
The diagnosis of allergic diseases is performed either by skin prick test in vivo or the 
detection of specific serum IgE antibodies in vitro. For both applications recombinant 
allergens were found superior to allergen extracts. A study including 156 patients with 
atopic eczema found IgE antibodies recognizing a Malassezia furfur extract or 6 
recombinant Malassezia furfur allergens (Mal f 1, Mal f 5-9) in 47% or 55% of the 
patients, respectively (148). Future allergy diagnosis might be based on microarray 
technology, which allows simultaneous screening of small amounts of serum for IgE 
antibodies binding to panels of recombinant allergens (149, 150). 
A detailed diagnosis allows determination of a component-resolved sensitization pattern, 
which allows patient-tailored allergen-specific immunotherapy (SIT), the only curative 
treatment for allergic diseases. SIT is used since almost 100 years and based on the 
repeated administration of the sensitizing allergen. Since different patients exhibit 
different patterns of allergen recognition, a patient-tailored immunotherapy with 
(combined) single recombinant allergens selected according to the patient’s reactivity 
profile might improve therapeutic success compared to the use of a crude allergen 
extract. In addition immunotherapy with recombinant allergens allows the use of optimal 
concentrations of the relevant allergens while excluding allergens not recognized by the 
patient, and thus avoiding de novo sensitization to proteins supplied in suboptimal 
concentrations. Successful immunotherapy depends on the ability of the used vaccine to 
modulate the specific T cell response without binding IgE on the surface of effector cells 
(151), which bears the danger of inducing anaphylactic side-effects. Genetically 
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engineered recombinant proteins, so-called hypoallergens, meet these demands by 
reducing IgE-binding and adverse effects, while maintaining T cell reactivity and the 
therapeutic potential (152, 153). 
5 .6 .3  IgE cross- react iv i t y  o f  a l le rgens  
In clinical practice monosensitization is rarely observed because the majority of allergic 
patients reacts to various allergens. This is either due to polysensitization or to cross-
reactivity among homologous molecules present in different allergenic sources. Cross-
reactivity results from molecular mimicry mediated by sharing of common B or T cell 
epitopes by two or more antigens. 
T cell epitopes are linear peptides consisting of 13-25 amino acid residues (154) whereas 
B cell epitopes are mostly conformational. They cover a surface area of 650-900 Å2, 
involving 15-22 amino acid residues of which 5-6 are energetically important for antibody 
binding (155, 156). Hence, the structure of a protein is crucial for IgE-binding. Similar 
protein folds can be found among proteins with 25% sequence identity, while cross-
reactivity is rare below 50% sequence identity (157). 
Groups of phylogenetically conserved proteins from distant species showing IgE binding 
capacity are referred to as pan-allergens. The first identified representatives were the 
major birch pollen allergens Bet v 1 and Bet v 2. Bet v 1 homologues have been detected 
in other pollen (158), as well as in foods such as apple (159), pear, celery (159), carrot 
(160), peanut (161), hazel nuts (162), or cherry (163). Bet v 2 is a member of the protein 
family of profilins, which are highly conserved and responsible for cross-reactivity among 
botanically unrelated species of fruits, vegetables, and pollen (164, 165). Interestingly, 
Bet v 2 also shares structural similarity and cross-reacts with human profilin (166) (see 
chapter 5.6.3). Other families of pan-allergens are enolases (167), heat shock proteins 
(168), ribosomal (169) and peroxisomal proteins (170), manganese superoxide 
dismutases (MnSOD) (171), cyclophilins (172), and thioredoxins (173), which are 
responsible for cross-reactivity between phylogenetically different species, including 
pollen, foods, allergenic moulds, yeasts and even human self-antigens. 
During the past few years the three-dimensional structures of an increasing number of 
allergens have been determined by X-ray crystallography or NMR spectroscopy. 
Although crystal structures have failed to elucidate the reasons why some proteins are 
allergenic and others are not, they have contributed substantially to our understanding of 
molecular interactions and thus cross-reactivity at the molecular level. It is possible to 
reliably predict cross-reactive B cell epitopes by homology modeling based on the 
comparison of 3D structures. Only amino acid residues, which are conserved in both 
primary sequences and at least partially exposed to solvent can account for cross-
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reactive B cell epitopes. Superimposition of the crystal structures of the fungal allergens 
Asp f 6, Mala s 6, and Mala s 13 with the structures of human MnSOD, cyclophilin, and 
thioredoxin, respectively, allowed the identification of patches of conserved amino acid 
residues, which most probably constitute cross-reactive B cell epitopes (Figure 5) (80, 82, 
171). 
Site-directed mutagenesis can corroborate these results and elucidate the actual 
contribution of a single amino acid residue to IgE-binding and cross-reactivity (174). 
Moreover, these findings allow the rational design and production of a molecule with 
reduced IgE-binding capacity, useful as candidate vaccine that might induce 
desensitization to a whole group of pan-allergens. 
 
 
 
Figure 5. Prediction of cross-reactive B cell epitopes by homology modeling. A. 
Superposition of Mala s 13 (pink) on human thioredoxin (blue) reveals large structural similarities 
between the two homologous proteins. In Mala s 13 the first α-helix of is shortened due to a 
deletion of two amino acids (D), while an insertion of two additional residues leads to an additional 
small α-helix (I). The N- and C-termini are designated N and C, respectively. B-D. Predicted cross-
reactive B cell epitopes are illustrated on the solvent-accessible surface of Mala s 13. Amino acid 
residues that are identical in Mala s 13 and human thioredoxin and at least 50% or between 30% 
and 50% solvent-exposed in both proteins are shown in pink or blue, respectively. (From Limacher 
A et al. (82)) 
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5 .6 .4  IgE- react ive  se l f -ant igens  
Already in 1941 it was demonstrated that human skin dander is able to trigger immediate 
type skin reactions in patients with severe AE (175). However, the observation that IgE-
mediated autoreactivity might play a role in the pathogenesis of AE was not further 
followed, until modern molecular biology led to the identification of IgE-binding self-
antigens. This allowed the explanation of the observed phenomenon on the basis of 
molecular mimicry and cross-reactivity. 
The first described self-antigen was profilin (164), which was identified by data bank 
searches and found to cross-react with the major birch pollen allergen Bet v 2. To date 
several IgE-binding self-antigens associated with AE are described and most of them 
share high homology to conserved environmental allergens, such as human MnSOD 
(132), ribosomal protein P2 (169), cyclophilin (172), and thioredoxin (173). Moreover, four 
self-antigens, namely SART-1 (Hom s 1) (176), α-NAC (Hom s 2) (177), BCL7B (Hom s 
3) (178), and cytokeratin type II (Hom s 5) (178) that do not share homology to known 
environmental allergens have been identified. 
All these proteins were recombinantly produced and shown to bind IgE of sera of patients 
suffering from AE, to induce the proliferation of T cells, and to elicit immediate type I 
hypersensitivity reactions in skin test challenges in patients sensitized to the 
corresponding environmental allergen (83). In addition Hom s 2 is able to induce the 
release of IFN-γ in cultured peripheral blood mononuclear cells (PBMC) of atopic 
individuals, leading to disintegration of respiratory epithelial cell layers and apoptosis of 
skin keratinocytes (179). 
The observed cross-reactivity between human self-antigens and environmental allergens 
raises the question of primary sensitization. Primary sensitization against human self-
antigens is rather unlikely since most of the individuals examined so far are not sensitized 
exclusively to the self-antigen but also react to homologous environmental allergens 
(171). Thereby the IgE as well as the cellular immune response against the 
environmental allergen are usually stronger compared to the reaction against the 
endogenous counterpart (171). These observations support the assumption that 
autoreactivity is initiated by sensitization against an environmental allergen, leading to 
inflammation and tissue damage. Thereby intracellular proteins are released as a 
consequence of inflammatory processes and become accessible to the immune system. 
These proteins are supposed to cross-react with IgE-antibodies primarily raised against 
the homologous environmental allergens. In addition, cellular stress during the 
inflammatory response induces the upregulation of stress-inducible proteins such as 
MnSOD (81). In a Th2-prone environment self-antigens may induce the de novo 
production of IgE autoantibodies and cross-link IgE bound on mast cells or basophils 
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inducing mediator release. Autoreactive T effector cells may elicit apoptosis of 
keratinocytes via the secretion of IFN-γ and FasL and thus contribute to the perpetuation 
of the symptoms. The hypothesis that IgE-mediated autoreactivity plays a relevant role in 
the pathogenesis of chronic atopic diseases like AE is in accordance with clinical 
observations showing that exacerbation of the disease can also occur in the absence of 
exposure to environmental allergens (180). 
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6 Aim of the thesis 
It has been known for more than 60 years that human skin dander can trigger immediate 
type skin reactions in AE patients. Moreover, in clinical practice exacerbations of the 
disease are frequently observed in the absence of environmental allergens. These 
observations might be due to cross-reactivity of human proteins showing structural 
similarity with phylogenetically conserved allergenic proteins. In fact, human homologues 
of environmental allergens are able to elicit type I skin reaction in patients sensitized to 
the corresponding environmental allergen, supporting a pathogenic role for IgE-mediated 
autoreactivity in AE. Several IgE-binding self-antigens such as MnSOD, cyclophilin, and 
thioredoxin are known and already characterized in deep molecular detail. However, the 
extent of the repertoire of IgE-binding self-antigens associated with, AE and their role in 
the pathogenesis are still largely unknown. 
 
Therefore, the aim of this thesis was to study IgE-mediated autoreactivity in AE by 
 
1. Identification of new self-antigens associated with AE by high-throughput screening 
of a human phage-surface display library with serum IgE from AE patients; 
2. Cloning, recombinant production, and purification of selected human self-antigens; 
3. Characterization of their immunological properties with respect to antibody-binding, 
induction of mediator release from basophils, and activation of T cells from 
sensitized AE patients; 
4. Analysis of the expression of self-antigens in the skin of AE patients and healthy 
individuals. 
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7 Results 
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Abst ract  
Background: Atopic eczema is the most common chronic inflammatory skin disease. 
Recent data demonstrate the presence of autoreactive serum IgE antibodies correlating 
with the severity of the disease. 
Objective: Although several IgE-binding self-antigens have been reported, the whole 
repertoire of IgE-binding self-antigens is unknown. We aimed to estimate the repertoire 
size of autoreactive proteins related to atopic eczema, clone, produce, and characterize 
humoral and T cell responses against novel self-antigens. 
Methods: Phage surface displayed human cDNA libraries were enriched for clones 
binding to serum IgE from atopic eczema patients and screened by high-throughput 
technology. Selected clones were used to produce the encoded proteins for further 
testing their IgE-binding ability in Western blots and ELISA, to induce proliferative 
responses in PBMC, and mediator release from basophils of sensitized individuals. 
Results: 140 sequences encoding potential IgE-binding self-antigens associated with 
atopic eczema were identified. 16 sequences encoded already described self-antigens. 3 
new sequences showed homology with environmental allergens, 86 encoded known 
human proteins, 7 predicted proteins, and 28 showed sequence identity with genomic 
contigs. Immunoblotting and ELISA experiments showed the presence of IgE-antibodies 
in sera from atopic eczema patients to five selected recombinant self-antigens. They 
were able to induce PBMC proliferation and mediator release from basophils of atopic 
eczema patients who have self-antigen-specific IgE antibodies. 
Conclusion: The data demonstrate a broad spectrum of at least 140 IgE-binding self-
antigens associated with atopic eczema. By binding IgE-antibodies or activating specific 
T cells they might promote and/or perpetuate existing skin inflammations. 
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In t roduct ion  
The description of “autoreactivity” goes back to the early last century when the sensitivity 
of individuals to human skin dander was demonstrated (175, 181). The observation that 
autoreactivity might play a role in the pathogenesis of atopic eczema (AE) was not further 
followed, until progress in molecular biology allowed isolation of cDNAs encoding IgE-
binding proteins (182, 183) and production of recombinant self-antigens (184). 
Interestingly most of these autoantigens have been isolated using sera of patients 
suffering from AE (178, 185). AE is a chronic relapsing inflammatory skin disease 
characterized by severely itchy, red, dry, and crusted skin and has a great impact on life 
quality of affected individuals. The pathogenesis of AE is likely to result from a 
combination of a defective skin barrier and inappropriate immune responses with 
contribution of genetic and environmental factors (186, 187). Environmental triggers for 
AE can be different life style factors, stress, allergens, and microorganisms (186). In 
addition, there is increasing evidence that IgE-mediated reactions to self-antigens could 
play an essential role in the pathogenesis of AE (188, 83). Recombinant human self-
antigens with high homology to environmental allergens like manganese-dependent 
superoxide dismutase (MnSOD) (132, 189), ribosomal P2 protein (169), cyclophilin (172, 
80), and thioredoxin (173, 82) have been shown to bind IgE from sera of AE patients , 
elicit proliferation of peripheral blood mononuclear cells ex vivo, and induce immediate 
type I hypersensitivity skin reactions exclusively in patients sensitized to the 
corresponding homologous environmental allergen. Moreover, human MnSOD, which 
alone elicits an eczematous reaction in atopy patch tests, is up-regulated in lesional skin 
of AE patients (81). These data provide strong evidence for a causal implication of 
autoreactivity in the pathogenesis of AE. 
Other human self-antigens described as Hom s 1 (176), Hom s 2 (179), Hom s 3 (188), 
and Hom s 5 (188) lack sequence homology to known environmental allergens. In 
contrast, Hom s 4 shows homology to a subfamily of calcium-binding allergens from 
plants and fish (190). However, all these self-antigens are able to cross-link specific IgE 
on effector cells as demonstrated by their ability to elicit immediate type I skin reactions. 
Recently it has been shown that Hom s 2-stimulated peripheral blood mononuclear cells 
(PBMC) of atopic and non-atopic individuals secrete IFN-γ, which mediates damage of 
epithelial cells and apoptosis of keratinocytes (179). Strong type I skin reactions, 
induction of keratinocyte apoptosis, and the observation that the level of specific 
autoreactive IgE-antibodies correlate with the severity of the disease (81) further suggest 
the involvement of autoreactivity in the pathogenesis of AE. 
Although several self-antigens have been described (83) and some characterized in deep 
molecular and structural details (189) (80) (82), the whole spectrum of IgE-binding self-
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antigens associated with AE is still largely unknown. Therefore, we probed the repertoire 
of IgE-binding self-antigens by screening a human cDNA library displayed on phage 
surface with serum IgE of AE patients. High-throughput screening of cDNA libraries 
displayed on page surface by affinity selection and high-density arrays is a rapid method 
for the identification of IgE-binding clones (191) and yielded during this work a long list of 
140 discrete sequences potentially encoding IgE-binding proteins. Seven sequences, 
including the known self-antigens cyclophilin B and thioredoxin as positive controls, were 
chosen to test the specificity of the enrichment procedure through cloning, production, 
and characterization of the recombinant self-antigens. 
  
35 
Resu l t s  
Methods  
Cons t ruc t ion  and  sc reen ing  o f  human  phage  su r face  d isp layed  cDNA 
l i b ra r ies  
A human cDNA library was constructed from human lung mRNA in phagemid pJuFo3 
and displayed on the surface of filamentous phage M13 as described (191) (137). Affinity 
selection of phages displaying human proteins was performed by four consecutive 
biopanning rounds against three different serum IgE pools from AE patients immobilized 
to microtiter plate wells (MaxisorpTM; Nunc, Roskilde, Denmark) through passively 
absorbed mouse anti-human IgE mAb TN142 (137). After the fourth round, eluted 
phagemids from the three selections were independently plated on 20 x 20 cm square 
plates at a density of 5-10’000 colonies/plate and grown overnight at 37°C. 2688 single 
colonies for each phagemid population were robot-picked and arrayed onto 7 medium-
filled 384 well plates. After overnight growth, cDNA inserts of all picked clones were 
amplified by high-throughput PCR using a PTC-225 thermal cycler (Tetrad, MJ Research 
Inc., Watertown, MA) and gridded in duplicates onto filter membranes to produce 
hybridization filters. 24 Filter hybridizations using DIG-labeled PCR probes derived either 
from known self-antigens or from the sequences of randomly selected clones were 
performed as described (192). Positive clones were scored using the image analysis 
package VisualGrid (GPC, Munich, Germany). Matrices of hybridization patterns were 
compared using the program Hybcompare (191). Inserts and PCR products were 
sequenced using dye-terminators on an automated sequencer (ABI-Perkin Elmer, Foster 
City, CA). Homology searches were performed with BLAST and the Genetic Computer 
Group program FASTA (193). 
 
C lon ing ,  p roduc t ion ,  and  pur i f i ca t ion  o f  r ecomb inan t  human  p ro te ins  
The coding sequences of the selected human proteins were amplified by PCR from a 
commercial human lymphoma cDNA library (U937, Stratagene, La Jolla, CA) with 
sequence-specific primers (Table 2), subcloned into the high-level expression vector 
pET17b (Novagen, San Diego, USA) and transformed into E. coli BL21 (DE3) star pLysS 
strains (Invitrogen, Groningen, The Netherlands). After verification by DNA sequencing, 
clones containing correct inserts were used for the production of His6-tagged recombinant 
proteins. Exponentially growing cultures were induced with 1 mM isopropyl-β-D-
thiogalactoside (Fermentas, Burlington, Canada) at an OD600 of 0.6. After 5 hours further 
incubation at 37°C cells were harvested by centrifugation (4000 x g, 10 min, 4°C) and 
lysed under denaturing conditions. To desalt and reduce LPS contaminations the cleared 
E. coli lysate was applied to Sephadex G-25 columns (GE healthcare, Chalfont St. Giles, 
UK). Subsequently, recombinant proteins were purified via Ni2+-chelate affinity 
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chromatography conditions using 5 ml HisTrap FF columns (GE healthcare) as described 
(194). To obtain soluble proteins, eluted fractions were dialyzed against ultra-pure water. 
Molecular size and purity of the His6-tagged fusion proteins were determined by SDS-
PAGE (NuPAGE; 12% Bis-Tris, Invitrogen). 
Endotoxin concentrations were determined by limulus amoebocyte lysate assay 
(Cambrex, Walkersville, USA). 
 
 
human 
protein 
GenBank 
Acc. No. primer 
MW 
(kDa) 
actin-α NM_001613 
5’-primer: 5’-cgcggatccatgtgtgaagaagaggacagc-3’ 
42 
3’-primer: 5’-cccaagcttagaagcatttgcggtggac-3’ 
tubulin- α NM_006009 
5’-primer: 5’-cgcggatccatgcgtgagtgcacttccatc-3’ 
50 
3’-primer: 5’-cccaagcttagtattcctctccttcttcc-3’ 
eIF6 NM_002212 
5’-primer: 5’-cgcggatccatggcggtccgagcttcg-3’ 
27 
3’-primer: 5’-cccaagcttaggtgaggctgtcaatgagg-3’ 
HLA-DR- α K01171 
5’-primer: 5’-cgcggatccatcaaagaagaacatgtgatcatcc-3’ 
24 
3’-primer: 5’-cccaagcttacagaggccccctgc-3’ 
RP1 X94232 
5’-primer: 5’-agggaattccctgggccgacccaaacc-3’ 
39 
3’-primer: 5’-cccaagcttcagtactcttcctgctgcg-3’ 
cyclophilin B NM_000942 
5’-primer: 5’-ggggatccatgaaggtgctccttgccgccgcc-3’ 
22 
3’-primer: 5’-cccaagcttctactccttggcgatggc-3’ 
thioredoxin X77584 
5’-primer: 5’-cgggatccatggtgaagcagatcgagagc-3’ 
12 
3’-primer: 5’-cccaagcttagactaattcattaatggtggcttccagcttttcc-3’ 
Table 2. GenBank accession number (Acc. No.), PCR primer pairs used for cloning, and 
predicted molecular weight (MW) of selected human self-antigens. The recognition sites of 
BamHI (ggatcc), EcoRI (gaattc) and Hind III (aagctt) restriction enzymes used for cloning are 
underlined. Acc. No.: Accession Number; MW: molecular weight 
 
Wes te rn  b lo t  ana lyses  
Recombinant proteins were separated on NuPAGE 12% Bis-Tris polyacrylamid gels 
(Invitrogen) under reducing conditions and transferred to Hybond-P PVDF membranes 
(GE healthcare). Non-specific binding sites were blocked with 5% skimmed milk in PBS, 
0.5% Tween-20 prior incubation of the membranes with sera, followed by primary mouse 
anti-human IgE mAb TN142 (195) and secondary PO-labeled sheep anti-mouse IgG mAb 
(GE healthcare). Bound IgE was visualized using ECL Plus Western Blotting Detection 
Reagents (GE healthcare). 
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IgG,  IgG1 ,  IgG3 ,  IgG4 ,  IgA ,  and  spec i f i c  IgE  EL ISA 
Specific binding of serum IgG, IgG1, IgG3, IgG4, IgA, and IgE to recombinant human 
proteins was analyzed by direct solid phase ELISA. Polystyrene microtiter plates 
(Maxisorp) were coated with 5 μg/ml of recombinant protein and processed as described 
(196). Bound antibodies were detected with a primary antibody specific for the different 
isotypes: AP-conjugated goat anti-human IgG (Pierce, Rockford, USA); NL16 mouse anti-
human IgG1 (Oxoid, Hampshire, United Kingdom); PO-conjugated mouse antihuman 
IgG3 (Zymed, Wien, Austria); RJ4 mouse anti-human IgG4 (Oxoid); PO-conjugated rabbit 
anti-human IgA (Dako, Glostrup, Denmark); TN142 mouse anti-human IgE (195). IgG1, 
IgG4, and IgE were visualized with a secondary goat AP-conjugated anti-mouse 
IgG(H+L) antibody (Pierce). After addition of the specific substrates (1.5 mg/ml di-Sodium 
4-nitrophenyl phosphate (Sigma-Aldrich, St. Louis, USA) in Diethanolaminbuffer pH 9.8 
(AP-conjugated antibodies) or 1.5 mg/ml o-phenylenediamine dihydrochloride (Sigma-
Aldrich) in citrate buffer (PO-conjugated antibodies), absorbency was measured at 405 
nm. 
 
Ac t i va t ion  o f  basoph i l s  
100 μl of heparinized venous blood was stimulated with recombinant self-antigens (1 μM), 
0.9% NaCl or anti-IgE monoclonal antibody (1 μg/ml) at 37°C for 20 min. After inhibiting 
Ca2+-dependent cell-signaling with 20 mM EDTA, the cells were stained with anti-CD63-
FITC and anti-CD203c-PE or anti-IgG1-FITC and anti-IgG1-PE (all from Beckman 
Coulter, Fullerton, USA) as isotype control, and analyzed by flow cytometry (EPICS XL-
MCL, Beckman Coulter). Basophils were identified by the expression of CD203c (197) 
and activation of the cells was analyzed by the up-regulation of CD63 (198). Flow-Count 
Fluorospheres (Beckman Coulter) were used to determine absolute cell counts. 
 
Pa t ien ts  and  con t ro l  sub jec ts   
71 adult patients suffering from AE, 24 healthy individuals and as an additional control 
group 12 patients with psoriasis of both sexes were recruited and carefully examined 
regarding clinical history, clinical symptoms, medications, or other treatments. Atopic and 
non-atopic eczema were diagnosed according to the criteria of Hanifin and Rajka (199) 
and the EAACI recommendations (60). Severity of the eczema was determined by the 
SCORAD index (200). Total and allergen-specific serum IgE-levels were analyzed by the 
ImmunoCap system (Phadia, Uppsala, Sweden) and ELISA, respectively. Patients’ 
characteristics including sex, age, diagnosis, SCORAD, and total serum IgE levels are 
reported on Table 3. Patients with total serum IgE levels > 100 kU/l and negative specific 
IgE and skin prick test to house dust mite, tree pollens, grass pollens, weed pollens, and 
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mould extract were assigned to the group of non-atopic eczema. The characteristics of 
this group of patients are reported on a separate Table (Table 4 in the Online 
Repository). The study protocol was approved by the ethics committee of the University 
of Zürich. A full explanation of the procedure was given to all participants, and their 
written consent was obtained before starting. 
 
S ta t i s t i ca l  ana l ys is  
All statistical analyses were performed in GraphPad Prism 5. Patients’ characteristics 
were compared using unpaired t-test, correlations between different antibody-isotypes 
determined by calculating Spearman’s rank correlation coefficient. 
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Resul ts  
I den t i f i ca t ion  o f  cDNA c lones  po ten t ia l l y  encod ing  IgE-b ind ing  se l f -
an t igens  
Screening of a human phage surface displayed cDNA library with serum IgE from three 
different pools of AE patients, yielded large populations of phage putatively expressing 
IgE-binding self-antigens. In the first screening round a set of filters were consecutively 
hybridized with dioxigenin-labelled probes derived from the known autoallergens MnSOD 
(189), P2 ribosomal protein (169), and profilin (166). 2342 (29%) of the 8064 analyzed 
clones hybridized with the known sequences. Direct sequencing of the inserts from 50 
randomly selected hybridization negative clones yielded 16 new sequences. Consecutive 
hybridization of the arrayed library with labeled probes of these 16 inserts allowed the 
identification of additional 3766 (46.7%) hybridization positive clones. Sequencing of 
further 50 hybridization negative clones yielded 22 new, so far undetected sequences, 
which were used in a third hybridization round resulting in the identification of additional 
1728 (21.5%) hybridization positive clones. The remaining 228 hybridization negative 
clones (2.8%) were PCR amplified and directly 5’-sequenced. 72 clones (0.9%) gave no 
amplification products and among the remaining 156 clones (1.9%), 110 new sequences 
were found. Thus, after three rounds of hybridization including three already known 
sequences and 246 sequencing reactions, 99.1% of the 8064 clones could be assigned 
to 151 discrete sequences. 
 
Charac te r i za t ion  o f  the  sequences  
The 148 new sequences detected in addition to the known MnSOD, P2 ribosomal protein, 
and profilin, were submitted to blast analysis to tentatively assign the putative self-
antigens to known proteins. Ten sequences lacked to show relevant sequence identity to 
known proteins, probably due to the very short lengths of the ORFs encoded, and one 
clone resulted to be a contaminant (Table 5 in the Online Repository). The remaining 137 
sequences represented sequences present in the human genome. Among these 27 
sequences matched perfectly to genomic contigs derived from different chromosomes, 
one to the mitochondrion genome, three to chromosomal ORFs encoding putative 
proteins of 140, 194, and 416 amino acids, respectively, and four to predicted proteins. 
These sequences were not further investigated. The remaining 99 sequences, together 
with the known self-antigens MnSOD, P2 ribosomal protein, and profilin, build a potential 
repertoire of IgE-binding self-antigens involving at last 102 distinct human proteins (Table 
5 in the Online Repository). 
A first group of 16 sequences coding for human proteins were already described as 
autoreactive self-antigens. Among these actin-α, tubulin-α, translation initiation factor 6 
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(eIF6), HLA-DR-α, and RP1 were demonstrated to be IgE-binding self-antigens and 
further investigated in the present study. 
A second group includes calmodulin, myosin-1C, and transglutaminase. These three 
proteins, although not yet described as IgE-binding self-antigens, show homology to 
described environmental allergens from pollen (201), Blattella germanica (202), and 
Dermatophagoides farina (203). The largest group of 86 IgE affinity-enriched sequences 
coded for described human proteins without sequence homology to known allergens. 
As expected from the screening of a cDNA library, not all sequences span complete open 
reading frames. In fact, only six of the 102 sequences coding for known human proteins 
represented full length clones (Table 5 in the Online Repository). However, the fact that 
all described IgE-binding self-antigens were present among the selected clones indicates 
that the majority of the detected sequences could indeed code for IgE-autoreactive self-
antigens. 
 
Va l ida t ion  o f  se lec ted  IgE-b ind ing  se l f -an t igens  
Cloning and production 
Three out of the newly identified potential self-antigen sequences, namely actin-α, eIF6, 
and RP1 were detected only as single hybridizing spots among the 8064 clones 
analyzed. Two clones showed higher hit frequencies of 291 (HLA-DR-α) and 237 (tubulin-
α). These five clones were selected for further investigations together with cyclophilin B 
(172) and thioredoxin (82), two well-known self-antigens, included as positive controls. 
The sequences were amplified by PCR using gene specific primers (Table 2), subcloned 
as His6-tagged fusion-proteins into the high-level expression vector pET-17b and 
recombinantly expressed in E. coli BL21 (DE3) star pLysS. After purification by Ni2+ 
affinity chromatography, size and purity of the recombinant proteins were tested by SDS-
PAGE and Coomassie Blue staining. Production yields varied between 5 and 30 mg pure 
protein per liter culture, depending on the clone. The estimated molecular masses for the 
His6-tagged proteins were in good agreement with the values calculated from the amino 
acid sequences and were virtually pure (Figure 6a). LPS contaminations of the 
recombinant protein preparations were found to be in the range of 0.1 to 0.2 EU/μg 
protein. 
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Figure 6. a) Recombinant proteins (2.5 μg) were separated by SDS-PAGE and stained with 
Coomassie Blue. b) Specific IgE-binding of the recombinant self-antigens analyzed by Western 
blotting using sera from different individuals suffering from AE. 
Lane 1: actin-α; lane 2: tubulin-α; lane 3: eIF6; lane 4: HLA-DR-α; lane 5: RP1; lane 6: cyclophilin 
B; lane 7: thioredoxin; lane 8: molecular weight standard (kDa). 
 
 
IgE-binding in Western blot and ELISA 
The IgE-binding capacity of the selected self-antigens was first confirmed in Western blot 
using sera of AE-patients (Figure 6b).The prevalence of sensitization against the 
recombinant proteins was determined by ELISA (Figure 7). Sera of 71 AE patients and 24 
healthy controls were analyzed for IgE-binding to the pure recombinant proteins. Signals 
were considered positive when the measured A405 value was more than 3-fold higher than 
the mean A405 value of the healthy controls for the respective self-antigen. Applying these 
cut-off values 51 out of 71 (71.8%) AE patients showed variable patterns of IgE 
autoreactivity to one or more of the tested self-antigens, while none of the healthy 
controls and of the psoriasis patients used as a control group for a non-IgE related 
chronic inflammatory skin disease showed specific IgE above background against any of 
these proteins (Table 3). These data indicate that IgE-mediated autoreactivity is confined 
to patients suffering from AE. In detail, 15.5%, 21.7%, 25.4%, 8.7%, and 29.0% of the 
AE-patients had specific IgE for actin-α, tubulin-α, eIF6, HLA-DR-α, and RP1, 
respectively (Figure 7). The prevalence of sensitization against the known self-antigen 
cyclophilin was 9.2%, whereas 23.4% of the analyzed patients had thioredoxin-specific 
serum IgE. These values are in good agreement with the prevalence reported in previous 
studies (80) (82) (204). 
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Figure 7. IgE specific for human self-antigens. Specific IgE against recombinant self-antigens 
determined by ELISA in sera from 71 AE-patients (¡, upper panel), 12 psoriasis patients (, 
middle panel) and 24 healthy controls (, lower panel). The cut-off values for positive results are 
highlighted in grey and correspond to 3-times the mean of the healthy control group. 
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 AE patients psoriasis patients healthy controls 
 with IgE to       self-antigens 
without IgE to 
self-antigens  
number 51 20 12 25 
sex, female : male 30 : 21 12 : 8 6 : 6 9 : 15 
mean age, y 33.35 ± 12.70 39.35 ± 13.5 45.17 ± 9.20 29.00 ± 3.71 
total IgE, kU/ml 2598.05 ± 3749.52 876.95 ± 1547.93 87.14 ± 24.73 56.8 ± 38.52 
SCORAD 47.43 ± 23.93 44.12 ± 22.19 0 0 
atopic : non-
atopic eczema 38 : 13 15 : 5 - - 
Table 3. Characteristics of AE patients with and without IgE specific to self-antigens, 
psoriasis patients, and healthy controls. AE patients with autoreactive IgE antibodies show no 
differences in mean age (p ≤ 0.7095) and SCORAD index (p ≤ 0.7625) but have significantly 
elevated levels of total IgE (p ≤ 0.0002) compared to AE patients without autoreactive IgE 
antibodies. 
 
 
Beside IgE, the antibody-isotypes IgA, IgG, IgG1, IgG3 (Figure 10 in the Online 
Repository), and IgG4 (Figure 8) specific for eIF6 were analyzed. All AE-patients and 
healthy individuals showed detectable levels of eIF6-specific IgG in serum. However, AE-
patients had clearly elevated levels of specific IgG4 and IgA, while the levels of total IgG, 
specific IgG1, and specific IgG3 were comparable to healthy individuals. A significant 
positive correlation was found between the levels of specific IgE and IgG4 (Figure 8b) 
and between specific IgE and IgG (Figure 10b in the Online Repository). 
 
 
 
Figure 8. IgG4 specific for human eIF6. a) Specific IgG4 against recombinant eIF6 determined by 
ELISA in sera from 8 healthy controls (, HC), 12 psoriasis patients (, P), and 16 AE-patients (¡, 
AE). b) Correlation between eIF6-specific IgG4 and IgE analyzed by ELISA in sera from 16 AE-
patients and 8 healthy individuals. Spearman’s rank correlation coefficient was calculated. 
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IgE reactivity to self-antigens in patients with non-atopic eczema 
The mean age, ratio between males and females, and the SCORAD index were similar 
among the 51 patients with and the 20 patients without autoreactive IgE (Table 3). In 
contrast, total IgE values were significantly higher among the subset of patients 
sensitized to human self-antigens (p>0.0002). Interestingly, 13 of the 18 patients fulfilling 
the criteria for non-atopic eczema, defined as lack of sensitization to common 
environmental allergens and low levels of total serum IgE (60), showed IgE reactivity to 
self-antigens (Table 4 in the Online Repository). These patients might be sensitized to 
environmental allergens with sequence homology to self-antigens, which are not yet 
identified or might mount IgE responses as the result of a primary autosensitization. 
 
Basophil activation and proliferative responses 
The ability of the recombinant self-antigens to cross-link receptor-bound IgE on the 
surface of basophils was analyzed by the upregulation of CD63 on the surface of CD203c 
positive cells by flow cytometry. All recombinant self-antigens, except HLA-DR-α, were 
able to induce upregulation of CD63 on basophils from AE-patients sensitized to the 
corresponding self-antigen (Figure 9), suggesting that these proteins are indeed able to 
cross-link Fcε-receptors, which leads to mediator release and activation of the cells. In 
contrast, basophils from healthy individuals and from AE patients without antigen-specific 
serum IgE to self-antigens do not showed any upregulation of the CD63 surface marker 
upon stimulation with self-antigens (Figure 9). Moreover, PBMC of atopic patients 
sensitized to a given self-antigen showed specific proliferation upon stimulation with the 
antigen, whereas cells of healthy controls did not show self-antigen-specific responses 
(data not shown). 
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Figure 9. Activation of basophils. Numbers of activated basophils were analyzed by the 
expression of CD203c and CD63 after the stimulation with recombinant self-antigens, sodium 
chloride, or anti-IgE. a) Results of three representative AE-patients are shown. b) Self-antigen 
induced activation of basophils from blood of AE patients with self-antigen-specific IgE (upper 
panel), AE patients without self-antigen specific IgE (middle panel), and healthy controls (lover 
panel). 
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Discuss ion 
Skin test reactivity to self-antigens is assumed to play a role in AE (175, 181) but only 
recently the application of modern cloning methods allowed the characterization of IgE-
binding self-antigens at molecular level (188) (83). A first class of IgE-binding self-
antigens, with profilin being the first member described (166), includes families of 
phylogenetically conserved proteins sharing sequence homology with environmental 
allergens. Recombinant self-antigens like MnSOD (132), ribosomal P2 protein (169), 
cyclophilin (172), or thioredoxin (173) are able to bind serum IgE, induce T cell 
proliferation ex vivo in PBMC and strong skin test reactions exclusively in patients with 
serum IgE against the corresponding homologous environmental allergens (132, 169). 
Moreover, the demonstration that human MnSOD applied to healthy skin areas of AE 
patients is sufficient to elicit eczematous reactions (81) and that serum IgE 
autoantibodies target keratinocytes (204) strongly indicates a role of autoreactivity in the 
pathogenesis of AE. IgE autoreactivity to self-antigens with sequence homology to 
environmental allergens can be explained by shared B cell epitopes as shown by 
comparison of the solved crystal structures of environmental allergens and homologous 
human proteins (82, 80). However, Western blot analyses of protein extracts of human 
epidermis cell lines with serum IgE of AE patients revealed a large number of positive 
bands (204, 205). Screening of a λgt 11 expression cDNA library derived from human 
epithelial cells with serum IgE of AE patients allowed the identification of four cDNAs 
encoding self-antigens without significant sequence homology with known exogenous 
allergens (178). This raised the question about the size of the repertoire of IgE-binding 
self-antigens involved in AE, which should, according to the number of bands detected in 
Western blots, be much larger than those of the so far described molecules. In this work 
we aimed to estimate the repertoire size of IgE-binding self-antigens associated with the 
disease. High-throughput screening of a human cDNA library displayed on phage surface 
with serum IgE of AE patients revealed 140 diverse cDNAs potentially encoding 
autoreactive proteins. The presence of the majority of the so far described IgE-binding 
self-antigens among the selected clones points out that phage display is a suitable 
method for the fast and efficient isolation of self-antigens with affinity for serum IgE. To 
demonstrate the specificity of the selection, we cloned, expressed and investigated the 
IgE-binding capacity of five novel cDNAs coding for actin-α, tubulin-α, eIF6, HLA-DR-α, 
and RP1 that were detected either as single clones or at low frequency among the 8064 
screened single clones (Table 5 in the Online Repository). 
The prevalence of IgE sensitization among the AE-patients ranged from 8.7% to 29.0% 
(Figure 7), with the lowest frequency for HLA-DR-α and the highest for RP1, in good 
agreement with the frequencies reported for other IgE-binding self-antigens (83, 204). 
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Both AE-patients and healthy individuals had detectable levels of eIF6-specific serum IgG 
(Figure 10 in the Online Repository), supporting a previous study, which demonstrates 
IgG specific for the Aspergillus fumigatus allergen Asp f 3 in sera from healthy individuals 
as well as allergic patients (197). The levels of eIF6-specific IgG4 and IgA were elevated 
in sera from AE-patients compared to healthy controls and the levels IgG4 correlated 
directly with the levels of specific IgE (Figure 8). 
Except HLA-DR-α, all tested recombinant proteins were able to cross-link receptor-bound 
IgE on the surface of basophils and upregulate the expression of CD63 and CD203c, 
which correlates with mediator release (Figure 9). As HLA-DR-α failed to activate 
basophils from sensitized individuals, it is possible that HLA-DR-α displays only a single 
epitope, leading to monovalent IgE-binding without cross-linking of Fcε-receptors. 
Elimination of autoreactive cells displaying more than one epitope could represent an 
efficient mechanism to avoid breakdown of immune tolerance to an antigen constitutively 
expressed and therefore accessible to the immune system all the time, which would have 
deleterious consequences. 
Proliferation of PBMC of AE patients was seen in response to all recombinant self-
antigens in sensitized patients (data not shown), indicating an involvement of 
autoantigen-specific T cells in the pathogenesis of AE. 
Taken together, the ability of all five selected recombinant proteins to bind serum IgE, 
activate basophils, and induce the proliferation of PBMC of sensitized individuals 
demonstrates a high specificity of the high-throughput screening technology. Based on 
this fact, the majority, if not all, of the sequences presented (Table 5 in the Online 
Repository) probably encode IgE-binding self-antigens, indicating a broad repertoire of 
human proteins involved in the pathogenesis of AE. 
Like other complex diseases, AE is likely to be determined by many genetic factors 
interacting with environmental components (206). It is therefore not trivial to assess the 
contribution of each single determinant to the complex phenotype of AE. However, there 
is cumulating evidence that IgE-mediated autoreactivity to self-antigens can contribute to 
the exacerbation of eczematous reactions. The demonstration that IgE autoantibodies 
target keratinocytes in AE patients (204), that self-antigens can cause disintegration of 
respiratory epithelial cell layers and apoptosis of skin keratinocytes (179), and induce 
eczematous reactions in healthy skin areas of AE patients in atopy patch tests (81) 
provide clear evidence for an involvement of autoreactivity in the perpetuation of AE. 
Based on our results derived exclusively from adult patients we cannot answer the 
questions of how early the onset of IgE-mediated autoreactivity to self-antigens occurs or 
if such a sensitization can occur in absence of sensitization to environmental allergens. 
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These important questions will require investigation of a pediatric population in a following 
study. 
Of course avoidance of exposure is not an option for AE patients sensitized to self-
antigens. However, because IgE-mediated reactivity to self-antigens seems to be 
confined to patients with chronic long lasting AE (178, 169), determination of self-antigen-
specific IgE might open new ways for stratification of patients. Patients with IgE-mediated 
autoreactivity might therefore benefit from systemic therapeutic options like treatment 
with immunosuppressive agents, which should be limited to severe refractory AE cases 
(207). The availability of a long list of highly pure recombinant IgE-binding self-antigens 
builds a solid basis for future investigations aimed at clarifying the role of autoreactivity in 
the pathogenesis of AE. 
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Onl ine  repos i tory  
 
patient sex age 
[years] 
SCORAD total IgE 
[kU/l] 
self-antigen-specific IgE to* 
1 2 3 4 5 6 7 
1 f 37 14.30 44.60 + - - + + - - 
2 f 22 18.25 31.10 + + + + + - - 
3 f 24 18.50 15.20 - - - - + - - 
4 f 23 16.00 97.60 - - + - - + + 
5 f 43 31.70 92.70 - + + - - - - 
6 f 23 46.80 22.60 - - - - + - - 
7 f 25 47.50 97.00 - + + - + - - 
8 m 28 61.04 18.50 - + - - - - - 
9 f 20 31.30 99.40 + - - + + - - 
10 f 16 16.30 11.40 - - - - + - - 
11 m 27 54.60 95.70 - - - - - - + 
12 f 27 22.40 6.43 - - + - + - - 
13 f 27 37.50 28.70 - - - - + - - 
14 m 19 85.20 50.70 - - - - - - - 
15 m 42 60.00 2.94 - - - - - - - 
16 m 67 38.0 94.20 - - - - - - - 
17 m 46 7.50 35.40 - - - - - - - 
18 f 34 35.00 66.40 - - - - - - - 
 
Table 4. Characteristics of non-atopic eczema patients with and without autoreactive IgE. 
Self-antigen-specific IgE to human actin-α (1), tubulin-α (2), eIF6 (3), HLA-DR-α (4), RP1 (5), 
cyclophilin B (6), and thioredoxin (7) of non-atopic eczema patients are shown. 
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Figure 10. IgG, IgG1, IgG3, and IgA specific for eIF6. Levels of IgG (a), IgG1 (c), IgG3 (e), and 
IgA (g) specific for recombinant eIF6 were analyzed by ELISA in sera from 16 AE-patients (AE), 12 
psoriasis patients (P), and 8 healthy controls (HC). The correlation with eIF6-specific IgE levels is 
shown (b, d, f, h). Spearman’s rank correlation coefficients were calculated. 
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Clone ORFa) Database match gene 
Gene bank 
accession 
no. 
Amino 
acidsb) 
Sequ. 
contig 
(bp) 
Clone 
frequ. Ref
c) 
 
A) Human sequences described as self-antigen: 
R2b16 C SOD2 (manganese superoxide dismutase) NM_000636 198 657 1294 132 
P2 C RPLP2 (ribosomal P2 protein) NM_001004 115 460 892 169 
Profilin C PFN1 (profilin 1) NM_005022 140 793 156 166 
Cyp B C PPIB (cyclophilin B) NM_000942 216 893 238 172 
Cyp A C PPIA (cyclophilin A) NM_021130 165 703 5 172 
Cyp C C PPIC (cyclophilin C) NM_000943 212 1058 4 172 
TRX C TXN (thioredoxin) NM_003329 105 412 706 82 
R3j17 P alpha-NAC AJ278883 215 348 1 178 
P1m01 P KRT6A (cytokeratin II) NM_005554 564 456 1 178 
P7n01 P RPL3 (ribosomal protein L3) NM_000967 403 497 1 214 
R2n23 P HSP90AA1 NM_005348 732 836 12 168 
P6j22 P ACTA2 (actin alpha 2)  NM_001613 377 608 1 d) 
S1c02 P TUBA1a (tubulin alpha 1a) NM_006009 451 602 237 d, 213) 
P6j13 P EIF6 (translation initiation factor 6) NM_002212 245 745 1 d) 
R2k20 P HLA-DR alpha NM_019111 254 704 291 d) 
S2h03 P MAPRE2 (RP1) NM_014268 327 820 1 d) 
        
B) New human sequences homologous to environmental allergens: 
P3j02 P CALM2 (calmodulin 2) NM_001743 149 584 1 201 
R1o01 P MYO1C (myosin 1C) NM_033375 1028 470 270 215 
P7a22 P TGM2 (transglutaminase 2) NM_004613 687 872 1 203 
 
C) Described human proteins: 
P2h18 P CYP4B1 (cytochrome P450) NM_001099772 512 484 1 e) 
R3i16 P FLNB (filamin B) NM_001457 2602 965 474  
r2e02 P RPL4 (ribosomal L4 protein) NM_000968 427 974 192  
P4l04 P ACTL6A (actin-like protein 6A) NM_178042 387 807 1  
P5m06 P HIP1R (huntingtin interacting protein 1 related) NM_003959 1068 858 1  
P4n01 P PPT1 (palmitoyl-protein thioesterase 1) NM_000310 306 795 1  
R6d05 P HBEGF (heparin-binding EGF-like growth factor) NM_001945 208 775 1  
R2c14 P VPS24 (vacuolar protein sorting 24 homolog) NM_016079 222 769 1  
S1e18 P TPP1 (tripeptidyl peptidase I) NM_000391 563 868 1  
R3l05 P EFNA1 (ephrin-A1) NM_004428 205 917 81  
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S1a09 P PSAP (prosaposin) NM_001042466 526 989 14  
R3i23 P SFTPA2B (surfactant, pulmonary-associated protein A2B) NM_006926 248 1169 1  
P1b23 C SNRCP (small nuclear ribonucleoprotein polypeptide C) NM_003093 159 690 1  
S5m03 P SAT1 (spermine N1-acetyltransferase 1) NM_002970 171 1014 1  
P2j04 P TIMP3 (TIMP metallopeptidase inhibitor 3) NM_000362 211 697 1  
P3j20 P RHBDD2 (rhomboid domain containing protein 2) 
NM_0010404
57 223 714 1  
R3d03 P CHPT1 (choline phosphotransferase 1) NM_020244 406 680 1  
S3h17 P LRRC36 (leucine rich repeat containing protein 36) NM_018296 754 664 1  
S6g04 P P4HA2 (proline 4-hydroxylase) NM_001017973 533 737 1  
S1j21 P STK 10 (serine/threonine kinase 10) NM_005990 968 641 49  
S5k16 P HTATIP2 (HIV-1 Tat interactive protein 2) 
NM_0010985
20 276 893 1  
P1n01 P MTMR14 (myotubularin related protein 14) 
NM_0010775
25 650 888 1  
P5g20 P TRIM26 (tripartite motif-containing protein 26) NM_003449 539 583 1  
P1j19 P PSMA3 (proteasome subunit alpha 3) NM_002788 255 612 1  
S1p02 P LGALS3 (galectin 3) NM_002306 250 770 1  
P5c14 P STAB 1 (stabilin 1) NM_015136 2570 580 1  
S6e22 P GAB2 (GRB2-associated binding prot. 2) NM_080491 676 686 1  
S3e8 P PCK2 (phosphoenolpyruvate carboxykinase 2) NM_004563 640 596 1  
P1m24 P BSG 1 (basigin 1) NM_001728 385 589 1  
P6c12 P GABARAP (GABA receptor- protein) NM_007278 117 575 1  
P1h09 P H3F3B (H3 histone 3B) NM_005324 136 588 1  
S7l09 P ZHX3 (zink fingers and homeoboxes 3) NM_015035  956 580 1  
S5o05 P KIF13B (kinesin family member 13) NM_015254 1826 671 1  
S7f08 P UNC119B (unc-119 homolog B) NM_001080533 251 568 1  
P4g24 C HSPB1 (Heat shock 27 kDa protein 1) NM_001540 205 790 1  
R2m18 P PIK3R3 (phosphoinositide-3-kinase) NM_003629 461 570 35  
R3l03 P PSME3 (proteasome activator subunit PA28) NM_176863 267 557 53  
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S1e21 P (COQ9) Coenzyme Q9 homologue NM_020312 318 527 1  
S5a21 P UBE3C (ubiquitin protein ligase E3C) NM_014671 1083 596 1  
P3n24 P NCF4 (neutrophil cytosolic factor 4) NM_000631 339 593 1  
S1h20 P PPL (periplakin) NM_002705 1756 517 1  
P1n15 P TRAF2 (TNF receptor-associated factor 2) NM_021138 501 522 1  
P7d18 P MBTPS1 (membrane-bound transcription factor peptidase) NM_003791 1052 550 1  
S4m22 P ARF1 (ADP-ribosylation factor 1) NM_001024228 181 690 1  
P1d09 P DUSP6 (Dual specificity phosphatase 6) NM_001946 381 802 1  
R2d06 P EIF4E2 (translation initiation factor 4E2) NM_004846 245 563 1419  
R1n21 P GTF2I (general transcriptiopn factor II) NM_032999 998 483 1  
R4b22 P CAPNS1 (calpain) NM_001749 268 482 1  
P6h03 P JOSD1 (Josephin domain containing protein 1) NM_014876 202 579 1  
S1g15 P B4GALT5 (beta 1,4- galactosyltransferase) NM_004776 388 506 1  
P1g21 P DGKG (diacylglycerol kinase gamma) 
NM_0010807
44 766 471 1  
P3m15 P DAP3 (death associated protein 3) NM_033657 398 654 1  
S5c06 P UBN1 (ubinuclein 1) NM_001079514 1134 529 1  
P4g19 P CFL1 (cofilin 1) NM_005507 166 487 1  
P6d22 P BCAP31 (B-cell receptor-associated protein 31) NM_005745 246 432 1  
R1a01 P SYK (spleen tyrosine kinase) NM_003177 635 837 28  
R2i03 P BGN (biglycan) NM_001711 368 423 192  
P1h16 P VSIG4 (V-set and immunoglobulin domain containing 4) 
NM_0011004
31 305 577 1  
S3d08 P SLIT2 (slit homolog 2) NM_004787 1529 778 1  
S4h08 P CCNDBP1 (cyclin D- binding-protein 1) NM_012142 360 811 1  
R3d02 P SERPING1 (serpin peptidase inhibitor) 
NM_0010322
95 500 379 1  
R4k08 P MPG (methylpurine DNA glycosylase) NM_002434 298 429 1  
P6b04 P TOB2 (transducer of ERBB2) NM_016272 344 550 1  
P3a10 P LAMC2 (laminin gamma 2) NM_005562 1193 559 1  
R3c07 P BMP4 (bone morphogenetic protein 4) NM_130851 408 420 101  
S2c07 P ARF3 (ADP-ribosylation factor 3) NM_001659 181 549 1  
P5g08 P TPP2 (tripeptidyl peptidase II) NM_003291 1249 368 1  
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R2h18 P PKIG 3 (protein kinase inhibitor gamma) NM_181804 76 439 324  
P1i02 P SLC22A18 (carrier family 22, memb. 18) NM_002555 424 300 81  
P3h08 P ACTB (actin beta) NM_001101 375 781 1  
S3n19 P TMEM116 (transmembrane protein 116) NM_138341 245 1083 1  
S1m01 P MKNK2 (MAP kinase interacting serine/threonine kinase 2) NM_199054 465 530 285  
P5d12 P DEDD (death effector domain containing protein) 
NM_0010397
12 318 693 1  
P2j17 P JUNB (jun B proto-oncogene) NM_002229 347 534 1  
R3g23 P MED27 (mediator complex subunit 27) NM_004269 311 633 70  
R2e7 P (MMRN2) multimerin 2 NM_024756 949 813 1  
P7l04 P 
HGSNAT (heparan-alpha-
glucosaminide N-
acetyltransferase) 
NM_152419 635 450 1  
P6b07 P PBX2 (pre-B-cell leukemia homeobox 2) NM_002586 430 420 1  
R4m17 P FXYD6 (FXYD domain containing ion transport regulator 6) NM_022003 95 662 1  
P2i12 P BSPRY (B-box and SPRY domain containing protein) NM_017688 402 566 1  
R2f15 P CPNE2 (copine II) NM_152727 548 606 69  
R1c02 P MIF4GD (MIF4G domain containing) NM_020679 256 351 1  
P1a01 P ATP13A1 (ATPase 13A1) NM_020410 1086 446 1  
P3o13 P TRIM47 (tripartite motif-containing 47) NM_033452 638 550 1  
R2e21 P ANXA11 (anexin A 11) NM_145869 505 686 127  
R2o04 P ADAMTSL4 (ADAMTS-like 4) NM_019032 1074 814 23  
        
D) Predicted proteins: 
S6o18 P RNF187 (ring finger Protein 187) XM_928029 403 648 1  
R3c20 P LOC728054 XM_001128749 91 426 97  
P7o22 P LOC400927 NR_002821 148 511 1  
S4i16 ? LLNLR-294C8 AC099491 ? 587 1  
P4f02 P Chromosome 1 ORF 158 NM_152290 194 661 1  
P5m13 P Chromosome 14 ORF1 NM_007176 140 434 1  
R1m01 P Chromosome 20 ORF3 NM_020531 416 573 53  
        
E) Chromosomal contigs: 
P6k24  Mitochondrion complete genome NC_001807  290 1  
P7n09  Chromosome 1 genomic contig NT_004321  509 1  
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P1o09  Chromosome 1 genomic contig NT_032977  460 1  
R4o22  Chromosome 1 genomic contig NW_921351  579 1  
R4c19  Chromosome 2 genomic contig NT_022184  589 1  
P3c06  Chromosome 2 genomic contig NW_927808  550 1  
P4n22  Chromosome 2 genomic contig NW_921618  520 1  
R1f20  Chromosome 3 genomic contig NT_029928  493 1  
S7b11  Chromosome 4 genomic contig NT_022792  463 1  
S1h06  Chromosome 5 genomic contig NT_006713  772 1  
S2j13  Chromosome 5 genomic contig NT_006576  551 1  
S2o02  Chromosome 6 genomic contig NT_010498  553 1  
S1c20  Chromosome 7 genomic contig NT_007819  841 1  
P3g21  Chromosome 7 genomic contig NT_007758  511 1  
S1i04  Chromosome 9 genomic contig NT_008470  614 1  
R3n23  Chromosome 10 genomic contig NT_008583  637 1  
P4j23  Chromosome 11 genomic contig NT_033899  670 1  
R4i06  Chromosome 11 genomic contig NT_033927  602 1  
S4n06  Chromosome 11 genomic contig NT_033903  544 1  
R1e03  Chromosome 12 genomic conig NT_009714  506 1  
R1i02  Chromosome 13 genomic contig NT_009952  1013 1  
R2i19  Chromosome 13 genomic contig NT_024524  413 1  
R3e20  Chromosome 14 genomic contig NT_026437  489 1  
R6g13  Chromosome 15 genomic contig NT_010274  903 1  
R1j3  Chromosome 15 genomic contig NT_010194  948 1  
R2g09  Chromosome 16 genomic contig NW_926140  893 1  
S5n15  Chromosome 22 genomic contig NT_011519  489 1  
R2p09  Chromosome X genomic contig NT_011651  697 1  
 
F) Clones with very short inserts (1-4 amino acids): 10 
   
G) Empty clones: 72 
   
H) Contaminants from other libraries: 1 
 
Table 5: Characteristics of IgE-binding sequences. 
a) Predicted open reading frame of the isolated inserts: C, complete; P, partial. 
b) Number of amino acids predicted from the complete reading frames 
c) Reference describing the original environmental allergen 
d) This work 
e) Cytochrome C is described as allergen from fungi (Cur l 3) and grasses (Lol p 10, Poa p 10), 
however these proteins are not members of the cytochrome P450 protein family. 
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7.2 The IgE-binding self-antigens tubulin-α  and HLA-
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Abst ract  
Background: Atopic eczema is the most common chronic, relapsing, inflammatory skin 
disorder with an atopic background. Previous studies have shown that IgE-mediated 
reactivity to self-antigens plays a role in the pathogenesis of the disease. However, the 
expression of self-antigens associated with atopic eczema in the lesional skin is poorly 
investigated. 
Aim of the study: This study was aimed to show that IgE-binding self-antigens are 
overexpressed in atopic eczema lesions.  
Methods: Tubulin-α and HLA-DR-α, two recently described self-antigens, were stained by 
immunohistochemistry in skin specimens from chronic and acute atopic eczema lesions, 
unaffected skin from the same patients or skin from healthy controls. 
Results: The expression of tubulin-α and HLA-DR-α is upregulated in atopic eczema 
lesions compared to non-lesional or healthy skin and correlates with the number of 
infiltrating immune cells and the degree of inflammation. 
Conclusion: Upregulation of IgE-binding self-antigens in lesional skin of atopic eczema 
patients might further promote the existing inflammation and induce exacerbations of the 
disease in the absence of exposure to environmental allergens. 
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In t roduct ion  
Atopic eczema (AE) is the most common inflammatory skin disorder affecting up to 10-
20% of children and 1-3% of adults in industrialized countries (59). Multiple factors are 
involved in the pathogenesis of AE including genetic predisposition, impaired skin barrier 
function, microbial colonization, and sensitization against environmental allergens. In 
addition, IgE antibodies reacting with human self-antigens are supposed to be involved in 
the pathogenesis of the disease (83). 
Several IgE-binding self-antigens associated with AE were identified, such as profilin, 
ribosomal protein P2, manganese superoxide dismutase (MnSOD), cyclophilin, 
thioredoxin, and Hom s 1-5 (For a review see (83)). By screening a human cDNA library 
displayed on phage surface with immobilized serum IgE from AE patients we recently 
identified 140 additional IgE-binding self-antigens (208), demonstrating that a broad 
spectrum of IgE-binding self-antigens is associated with AE. Recombinant human self-
antigens characterized in detail were shown to bind serum IgE of AE patients, to induce 
mediator release from basophils, and to stimulate the proliferation of PBMC (166, 132, 
169, 82, 178). Moreover, serum IgE of AE patients targets keratinocytes and normal 
human epidermis (204) and the well-characterized self-antigen MnSOD is sufficient to 
elicit eczematous reactions if applied to healthy skin areas of AE patients (81). 
Interestingly, MnSOD expression is upregulated in lesional, but not in healthy skin areas 
of AE patients sensitized to the self-antigen, providing strong evidence for the 
involvement of autoreactivity in the exacerbation of an existing inflammation (81). 
During the present study we investigated the expression of two newly described self-
antigens, tubulin-α and HLA-DR-α (208), by immunohistochemistry in skin biopsies taken 
from acute and chronic AE lesions and non-lesional skin of the same patients, or from 
healthy controls. 
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Methods  
Pat ien t  se lec t i on  
Biopsies were taken from four AE patients and three healthy controls of both sexes. 
Diagnosis of AE was made according to the recommendations of the EAACI and severity 
of the disease was determined by the SCORAD index as described (81). Total and 
specific serum IgE against Malassezia sympodialis were determined by the ImmunoCap 
system (Phadia, Uppsala, Sweden). Healthy individuals had no history of allergy, asthma, 
or AE and normal total IgE levels. The characteristics of patients and controls are 
reported in Table 6. Permission to conduct this study was obtained from the Ethics 
Committee at Karolinska Hospital, Stockholm, and informed consent was given by all 
subjects. 
 
donor sex age (y) SCORAD Phadiatop total IgE (kU/l) 
IgE to 
Malassezia 
spp. (m70) 
AE 1 m 49 48 pos 2700 24 
AE 2 f 20 48 pos 2300 28 
AE 3 m 43 61 pos 1700 7.5 
AE 4 f 26 53 neg 81 <0.35 
HC 1 m 41 - neg 77 <0.35 
HC 2 f 23 - neg 11 <0.35 
HC 3 f 23 - neg 6.2 <0.35 
 
Table 6. Characteristics of patients and healthy controls. AE, atopic eczema; HC, healthy 
control; SCORAD, severity scoring of atopic dermatitis 
 
Immunoh is tochemis t ry  s ta in ing  
Immunohistochemistry staining was performed on cryostat-embedded skin specimens 
taken from lesional and non-lesional skin of AE patients or of healthy controls. Frozen 
sections were fixed in 50% and 100% acetone and incubated in 0.3% H2O2 in PBS to 
inhibit endogenous peroxidase activity. Non-specific binding was blocked with normal 
horse sera diluted 1:10 in 4% BSA, followed by incubation with avidin and biotin blocking 
solutions (Vector Laboratories, Burlingame, US). Human tubulin-α, HLA-DR-α, and CD3 
were detected with specific primary antibodies: mouse anti-human tubulin-α, clone TU-01 
(AbD Serotec, Kidlington, UK) diluted 1:250; mouse anti-human HLA-DR-α, clone 
TAL.1B5 (Dako, Glostrup, Denmark) diluted 1:12.5; mouse anti-human CD3, clone SK7 
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(BD Biosciences, Franklin Lakes, US) diluted 1:16. Mouse IgG1 (Dako) was used as 
isotype control. After incubation with biotinylated horse anti-mouse IgG secondary 
antibody (Vector Laboratories) diluted 1:10, biopsies were developed with ABC-elite 
solution (Vector Laboratories) and 3-amino-9-ethylcarbazole (Sigma, St. Louis, US) as 
substrate. All slides were counterstained with Mayer's hematoxylin and examined by 
standard bright field optics. 
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Resul ts  
Human tubulin-α and HLA-DR-α were stained by immunohistochemistry in skin biopsies 
taken from chronic lesions, positive APT reactions and non-affected skin of four AE 
patients or from healthy skin of three non-atopic individuals. 
A strong upregulation of tubulin-α expression was found in epidermal cells of chronic 
(Figure 11A) and acute AE lesions of all four patients tested. In contrast, tubulin-α 
expression was strongly reduced in keratinocytes from non-affected skin of the same 
patients (Figure 11B) and confined to stratum granulosum in the skin of the healthy 
individuals (Figure 11C). 
HLA-DR-α was highly expressed on infiltrating cells such as B cells, dermal dendritic 
cells, and Langerhans cells in chronic AE lesions (Figure 11D) and positive APT 
reactions (data not shown). In biopsies taken from non-affected skin of the same AE 
patient (Figure 11E) or from healthy donors (Figure 11F) HLA-DR-α expression was 
strongly reduced compared to inflamed skin. Moreover, the degree of HLA-DR-α staining 
correlated quite well with the degree of inflammation, determined by the numbers of 
infiltrating CD3+ T cells (Figure 11G) whereas only few CD3+ T cells were detectable in 
non-lesional skin of AE patients or in skin of healthy individuals (Figure 11H, I). Staining 
of the skin with mouse IgG1 used as isotype control were negative in all biopsies tested 
and independent from inflammatory processes as expected (Figure 11J-L). 
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Figure 11. Upregulation of tubulin-α and HLA-DR-α expression in AE lesions. Tubulin-α and 
HLA-DR-α were stained by immunohistochemistry in the lesional (A, D), non-lesional skin (B, E) of 
the same AE patients and in healthy skin (C, F). Infiltrating CD3+ cells (G, H, J) reflect the degree of 
inflammation. Results obtained for one representative AE patient and one healthy control are 
shown. Isotype control staining for lesional skin (J), non-lesional skin of the same patient (K), and 
skin of a healthy individual (L) is shown. 
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Discuss ion 
IgE-mediated autoreactivity is assumed to play a role in the multifactorial pathogenesis of 
AE and a broad spectrum of IgE-binding self-antigens has been described (83). They 
include proteins with a high degree of homology to environmental allergens (166, 132, 
169, 82, 80) as well as self-antigens without any sequence homology to known allergens 
(178). Autoreactivity to self-antigens sharing sequence homology to environmental 
allergens can be explained by molecular mimicry as clearly shown for MnSOD (132, 81), 
cyclophilin (80), and thioredoxin (82). These proteins are inducible by oxidative stress 
(209), a condition characteristic for inflamed skin of AE patients (210), and in fact it has 
been shown that MnSOD is moderately expressed in the skin of healthy individuals or in 
healthy skin areas of AE patients, but strongly upregulated in lesional skin areas (81). 
Moreover, application of human MnSOD to unaffected skin areas of AE patients in atopy 
patch tests is sufficient to elicit eczematous reactions in AE patients sensitized to 
MnSOD, highlighting the role of IgE-mediated autoreactivity in the exacerbation and/or 
perpetuation of AE (81). However, overexpression of other IgE-binding self-antigens in 
the inflammatory skin areas of AE patients has not been reported. During the present 
study we analyzed the expression of two IgE-binding self-antigens, tubulin-α and HLA-
DR-α, in lesional and non-affected skin of AE patients and in the skin of healthy 
individuals by immunohistochemistry. Both, tubulin-α and HLA-DR-α are detectable in 
epidermal keratinocytes and infiltrating immune cells, respectively. The expression of the 
self-antigens is upregulated in skin specimens taken from chronic AE lesions compared 
to unaffected skin of the same patients or skin from healthy individuals (Figure 11). These 
findings corroborate previous work, demonstrating that the IgE-binding self-antigen 
MnSOD is upregulated in inflamed skin of AE patients. The overexpression of self-
antigens in AE lesions provides targets for autoreactive serum IgE antibodies at the site 
of inflammation allowing the formation of IgE immune complexes that could target effector 
cells like mast cells and basophils. Clear evidences supporting this assumption are the 
ability of IgE-binding self-antigens to induce mediator release from basophils (208) and 
immediate type I skin reactions (132, 169, 82, 178, 80). Activation of effector cells results 
in the release of preformed mediators, production of cytokines, and initiation of an allergic 
tissue reaction, resulting in induction and maintenance of inflammatory skin responses 
(179). In summary, overexpression of IgE-binding self-antigens in lesional skin of AE 
patients seems to be a common phenomenon, which can explain the significant 
correlation observed between autoreactivity and severity of the disease (211). Since a 
relevant subset of about 30% AE patients shows IgE reactivity to a variety of human self-
antigens, it is likely that these reactions contribute to the exacerbation of AE in a subset 
of patients.  
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8 Final Discussion 
Characterized by typically distributed eczematous skin lesions, dry skin, and pruritus, AE 
severely impairs the quality of patients’ life. In addition, AE represents the most common 
chronic inflammatory skin disease and its prevalence still increases, causing rising health 
cost burdens to the society. To date allergen-specific immunotherapy is the only 
treatment to cure allergic diseases and is successfully used in clinical practice for the 
treatment of relatively simple allergic complications like insect venom allergy and allergic 
rhinitis. However, most of the clinical trials aimed to treat complex allergic disorders such 
as AE, or food allergy were inconclusive. To facilitate the management of AE and to 
define new therapeutic strategies, a detailed understanding of the molecular components 
involved in the development of AE and of the immunological mechanisms underlying the 
pathogenesis of the disease are required. 
 
Already in the 1940s, it was assumed that autoreactivity could play a role in the 
pathogenesis of AE since human skin dander elicits type I skin reactions in those 
patients. This concept was not followed further until the use of modern molecular biology 
methods allowed identification, cloning, and production of IgE-binding self-antigens. 
Detailed characterization of the IgE-binding self-antigens demonstrates that some human 
proteins can cross-react with environmental allergens due to shared features on primary 
and secondary structure levels. Some highly conserved IgE-binding self-antigens 
associated with AE such as MnSOD, cyclophilin, and thioredoxin were characterized in 
deep molecular detail in vitro and tested for skin test reactivity in vivo. In these cases 
cross-reactivity can be traced back to shared structural components between self-
antigens and environmental allergens. In addition, screening of a cDNA library 
constructed from a human epithelial cell line with serum IgE from AE-patients led to the 
identification of five additional IgE-binding self-antigens, designed Hom s 1-5. Out of 
these, Hom s 1-3 and Hom s 5 do not show homology to any known environmental 
allergen. 
Although many autoreactive self-antigens are described, the spectrum of IgE-binding self-
antigens is supposed to be far from being complete. Thus, the major aim of the present 
thesis was to estimate the extent of the IgE-binding self-antigen repertoire associated 
with AE. 
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8.1 Identif ication of a broad spectrum of self-
antigens associated with atopic eczema 
A human cDNA library displayed on phage surface was constructed and screened with 
serum IgE from AE-patients by high-throughput technologies. Sequencing of the enriched 
clones resulted in 140 diverse sequences. 
Among them, ten already described self-antigens were present, indicating a high 
specificity of the screening procedure. Five sequences showed homology to known 
environmental allergens, namely tubulin-α, ribosomal protein L3, calmodulin, myosin, and 
transglutaminase from storage mites (212, 213), A. fumigatus (214), pollen (128), 
Blattella germanica (www.allergome.org (215)), and Dermatophagoides farinae (203), 
respectively. Considering previous results on the IgE-binding capacity of conserved self-
antigens (171, 80, 82), human tubulin-α, ribosomal protein L3, calmodulin, myosin, and 
transglutaminase are supposed to cross-react with the corresponding environmental 
allergens. A large group of 90 sequences coded for human proteins without sequence 
homology to described environmental allergens. Seven sequences encoded putative 
proteins, 27 sequences matched to chromosomal contigs derived from different 
chromosomes, and one sequence matched to mitochondrial DNA. 
8.2 Production of recombinant self-antigens 
Out of the group of 90 sequences encoding human proteins without homology to known 
environmental allergens five sequences were randomly selected and together with the 
known self-antigens cyclophilin B and thioredoxin immunologically characterized in detail. 
The genes for actin-α, tubulin-α, eukaryotic initiation factor for translation 6 (eIF6), HLA-
DR-α, and RP1 were amplified by PCR from a human cDNA library using gene-specific 
primers and cloned as His6-tagged fusion proteins into a high level expression vector. 
The selected proteins were recombinantly produced in E. coli and purified by IMAC. A 
desalting step prior to IMAC reduced bacterial contaminations such as lipopolysaccharide 
(LPS). Highly pure protein solutions with concentrations in the range between 0.5-1.2 
mg/ml and LPS concentrations of 0.1-0.2 EU/μg protein were obtained for further 
investigations. 
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8.3 Immunological characterization of recombinant 
self-antigens 
Western blot experiments using sera of AE-patients confirmed the IgE-binding capacity of 
the recombinant self-antigens. The prevalence of sensitization among AE-patients was 
determined by ELISA and found to be 15.5%, 21.7%, 25.4%, 8.7%, and 29.0% for actin-
α, tubulin-α, eIF6, HLA-DR-α, and RP1, respectively. 9.2% of AE-patients had specific 
IgE against cyclophilin and 23.4% showed IgE-binding to thioredoxin. In summary, 51 out 
of 71 (71.8%) AE-patients had autoreactive IgE-antibodies to at least one of the tested 
self-antigens, while none of the healthy controls showed detectable levels of self-antigen-
specific IgE. These findings are in good agreement with previously reported frequencies 
of prevalence for other self-antigens (81, 204). Since all randomly chosen proteins bound 
serum IgE, the used screening system is suitable for an efficient isolation of allergens 
with affinity to IgE and most likely, all 140 newly identified sequences encode IgE-binding 
self-antigens. 
The mean age, the sex ratio, and the severity of the disease determined by the SCORAD 
index were similar among the groups of patients with and without autoreactive IgE. In 
contrast, total IgE values were significantly higher among the subset of patients showing 
IgE-mediated autoreactivity. 13 and five patients with and without autoreactive IgE, 
respectively, suffered from non-atopic eczema, defined by low total IgE-levels (<150 kU/l) 
and lack of sensitization to environmental allergens in routine assessments (60). 
Tubulin-α is described as allergen from the storage mites Tyrophagus putrescentiae (212) 
and Lepidoglyphus destructor (213). Both proteins share 94% identity with the human 
homologue. Inhibition experiments showed that human tubulin-α in the liquid phase is 
able to inhibit the binding of serum IgE to tubulin-α from Lepidoglyphus destructor coated 
onto the solid phase in ELISA. Thus, human and mite tubulin-α are cross-reactive due to 
common structural features and shared IgE-binding epitopes (data not shown). 
 
Next to specific IgE the antibody-isotypes IgA, IgG, IgG1, IgG3, and IgG4 specific for 
eIF6 were analyzed. AE-patients had elevated levels of specific IgA and IgG4 compared 
to healthy controls. In contrast, the levels of total specific IgG, specific IgG1, and IgG3 
were similar between AE-patients and healthy individuals. These findings corroborate 
previous reports that demonstrated the presence of IgG-antibodies specific for the A. 
fumigatus allergens in sera from healthy and allergic individuals (196, 195). 
 
AE is characterized by severe pruritus that is mainly due to the release of histamine from 
activated basophils and mast cells. Except HLA-DR-α all tested self-antigens were able to 
cross-link FcεR-bound IgE on the surface of basophils and to induce the release of 
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mediators, accompanied by the expression of CD63 (216, 198) and the upregulation of 
CD203c (197, 217). The failure of HLA-DR-α to cross-link FcεR might by due to only one 
IgE-binding epitope, resulting in monovalent IgE-binding. HLA-DR-α is exposed on the 
outer surface of professional antigen presenting cells and constantly accessible for the 
immune system. Thus, monovalent IgE-binding would prevent FcεR cross-linking and 
degranulation of basophils and mast cells, resulting in the absence of symptoms. 
 
Since T effector cells play an important role in the pathogenesis of AE by activating B 
cells to produce IgE, promoting inflammation in the skin, and inducing keratinocyte 
apoptosis, the presence of self-antigen-specific T cells was analyzed. Stimulation of 
PBMC of sensitized individuals with recombinant self-antigens resulted in dose-
dependent proliferation of the cells, while cells of non-sensitized individuals or healthy 
controls did not proliferate. LPS concentrations 100-fold higher than those present in the 
recombinant protein solutions used were not able to induce proliferation of PBMC, 
indicating that the observed proliferation is self-antigen-specific (data not shown). 
 
In summary, most if not all of the 140 human proteins identified during this work might 
serve as an IgE-binding self-antigen in AE since 1) a large number of potential IgE-
binding self-antigens associated with AE were identified by phage display techniques, 2) 
the IgE-binding capacity of five randomly selected self-antigens was verified by Western 
blot, ELISA, and basophils activation assays, and 3) the identified potential self-antigens 
share no obvious common feature. Moreover, 71.8% of the analyzed patients show IgE-
mediated autoreactivity against at least one out of five randomly selected self-antigens. 
Assuming that a long list of IgE-binding self-antigens associated with AE exists, most or 
even every AE patient might have autoreactive IgE-antibodies in serum. 
 
In general, several mechanisms may induce autoreactivity, including viral or bacterial 
superantigens,  bystander activation of autoreactive T cells by cytokines secreted in 
response to viral or bacterial pathogens (218), release of self-antigens during 
inflammation, and molecular mimicry. 
More than 90% of AE patients show colonization of the skin by the Gram-positive bacteria 
S. aureus, whose superantigenic enterotoxins activate T cells in an allergen-independent 
manner. These staphylococcal enterotoxins were shown to stimulate autoreactive T cells 
and induce exacerbations in experimental autoimmune encephalitis (EAE) mouse model 
of multiple sclerosis (219). In addition, environmental allergens activate various immune 
cells in AE, resulting in the release of cytokines and chemokines that may decrease the 
threshold for activation of autoreactive T cells (220, 221). The dermal inflammation 
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together with scratching leads to the damage of human cells and the release of self-
antigens, which are not accessible to the immune system under healthy conditions. 
Indeed, it has been demonstrated that IgE autoantibody levels increase after allergic 
inflammation and tissue damage (178, 222). Moreover, molecular mimicry is supposed to 
play a decisive role in inducing autoreactivity in AE since infections with pathogens, such 
as M. sympodialis expressing antigenic homologues of human proteins may promote the 
activation of potentially autoreactive cells (223). The cross-reactivity between conserved 
human self-antigens and structurally homologous environmental allergens was shown for 
tubulin-α. But also microbial peptides with limited sequence homology to human self-
antigens are effective activators of autoreactive T cells (224). Several bacterial and viral 
proteins have been shown to activate autoreactive T cell clones specific for myelin basic 
protein (MBP), the major self-antigen in multiple sclerosis. Interestingly, most of the 
stimulating bacterial and viral peptides show no obvious sequence similarity with the 
cross-reactive peptide from MBP, indicating that the antigenic surfaces rather than 
sequence similarity are decisive for peptide mimicry (225, 226). Thus, also human 
proteins without sequence homology to environmental allergens like eIF6 or RP1 might 
activate autoreactive T cells through molecular mimicry. 
8.4 Dermal expression of self-antigens 
The expression of actin-α, tubulin-α, and HLA-DR-α in skin biopsies of AE patients and 
healthy individuals was analyzed by immunohistochemistry. All three self-antigens were 
detectable in acute lesions, chronic lesions, and unaffected skin of AE patients, and in 
skin biopsies taken from healthy individuals. Actin-α was found in smooth muscle cells in 
the dermis such as musculus arrector pili associated with hair follicles and smooth 
muscle cells surrounding dermal blood vessels. Tubulin-α was mainly expressed in 
epidermal keratinocytes and the level of tubulin-α expression was increased in the 
epidermis of AE lesions compared to non-lesional skin of the same patient. The 
expression of HLA-DR-α on professional antigen-presenting cells such as Langerhans 
cells and IDEC correlated directly with the degree of dermal inflammation, determined by 
the number of infiltrating CD3+ T cells and hematoxylin-eosin staining. Thus, increased 
expression of tubulin-α and HLA-DR-α further promotes IgE-mediated autoreactivity 
during inflammatory processes. 
Incubation of skin biopsies from healthy individuals with sera from AE patients led to 
binding of serum IgE to keratinocytes, while no IgE-binding was detectable after 
incubation with sera from healthy individuals. This observation demonstrates that IgE 
antibodies present in sera from AE patients indeed bind their targets in the skin, strongly 
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indicating that IgE-mediated autoreactivity plays a role in the pathogenesis of AE (data 
not shown). 
8.5 IgE-mediated Reactivity to Self-Antigens: A 
Controversial  Issue 
Recent publications and our own data on IgE-mediated reactivity to self-antigens were 
critically analyzed and published as Review Article in International Archives of Allergy and 
Immunology: 
 
Zeller S, Glaser AG, Vilhelmsson M, Rhyner C, Crameri R. Immunoglobulin-E-mediated 
reactivity to self-antigens: a controversial issue. International Archives of Allergy and 
Immunology 2008; 145:87-93. 
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8.6 Conclusion and Outlook 
Within the present thesis 140 new self-antigens potentially associated with AE were 
identified. Five randomly selected proteins together with the known IgE-binding self-
antigens cyclophilin B and thioredoxin were shown to bind IgE in sera from AE-patients, 
to induce mediator release from basophils, and to stimulate the proliferation of T cells 
from sensitized patients. 
Among the repertoire of IgE-binding self-antigens several phylogenetically highly 
conserved proteins such as actin-α and tubulin-α are present. These self-antigens are 
supposed to cross-react with homologous environmental allergens due to molecular 
mimicry. Whether molecular mimicry is the only basis of IgE-mediated autoreactivity or 
whether sensitization to self-antigens can arise as a direct consequence of inflammatory 
processes remains to be elucidated. 
Except HLA-DR-α, all characterized IgE-binding self-antigens are intracellular proteins 
that are supposed to be released during inflammatory processes and thereby become 
accessible to the immune system. In contrast, HLA-DR-α is permanently displayed on the 
outer surface of antigen-presenting cells, but did not activate patients’ basophils most 
likely due to monovalent IgE-binding. Therefore, the detailed study of HLA-DR-α and 
further self-antigens that are secreted or exposed on the cell surface will be the subject of 
interesting future studies. 
Finally, a detailed analysis of patients’ characteristics and IgE-mediated autoreactivity 
might lead to the identification of subgroups of patients that are for instance at high risk to 
develop further atopic diseases or suitable for SIT. Thus, IgE-mediated autoreactivity 
could lead to the development of new diagnostic criteria for the stratification of AE 
patients in order to identify underlying disease mechanism aimed to offer the patients 
proper advice and treatment. 
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8.7 Statement of contribution to publications 
For the article entitled “Exploring the repertoire of IgE-binding self-antigens associated 
with atopic eczema” I performed all experiments (Figure 6-10) under the supervision of R. 
Crameri. C. Rhyner provided technical advice, N. Meyer and P. Schmid-Grendelmeier 
recruited the patients enrolled in my studies. 
 
For the short communication article entitled “The IgE-binding self-antigens tubulin-α and 
HLA-DR-α are overexpressed in the lesional skin of atopic eczema patients” I performed 
all experiments (Figure 11) with the technical support of C. Johansson and C. Rhyner 
under the supervision of A. Scheynius and R. Crameri. 
 
The review article “Immunoglobulin-E-Mediated Reactivity to Self-Antigens: A 
Controversial Issue” was written by myself under guidance of R. Crameri. A. Glaser, M. 
Vilhelmsson, and C. Rhyner provided experimental results. 
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